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Abstract 
Development of the metabolic syndrome is determined by a complex interaction of 
environmental and genetic factors and as with other complex human traits, disease 
gene identification is problematic due to a lack of statistical power and genetic 
heterogeneity in patients. Identifying genes that underlie metabolic syndrome risk 
factors will allow better understanding and development of treatments which would 
decrease disease health burden. The spontaneously hypertensive rat (SHR) is a 
widely studied model of insulin resistance and hypertension and, as in humans, the 
hypertensive phenotype clusters with metabolic traits. SHR was crossed with 
normotensive Brown Norway rats to develop the BXH/HXB recombinant inbred (RI) 
strain panel. 
In these studies this RI panel is being used to identify genomic regions influencing 
gene expression, termed expression quantitative trait loci (eQTL). Affymetrix 
microarray expression profiles from two tissues (fat and kidney) in the RI and parental 
strains were generated. Transcript abundance for each gene on the microarray was 
treated as a quantitative trait and these eQTL were defined as: cis-acting, and trans- 
acting. This work examines a subset of cis-acting eQTL (p.,: ý 10-4) to look for t: ) 
polymorphisms in the putative promoters of these genes. These polymorphisms may 
cause the differential expression detected in these strains and underlie the phenotypic 
variation seen. 
In silico comparative mapping was carried out to investigate the applicability of the 
detected rat cis-acting eQTL genes to human disease. This used human QTL for 
metabolic and cardiovascular phenotypes to identify rat cis-acting eQTL and their 
human orthologs as potential candidate genes. This analysis detected several genes 
with known involvement in human metabolic syndrome phenotypes and a large 
number of novel candidate genes that merit testing in human populations. 
The results demonstrate an integrated genome-wide expression profiling with linkage 
analysis approach and its use in identification of candidate genes which may underlie 
complex traits. 
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Chapter 1: Introduction 
1.1 Genetic dissection of complex traits 
Genetically complex traits, such as hypertension and the metabolic syndrome, are 
those diseases without a clear Mendelian pattern of inheritance; they tend to be highly 
prevalent and more common than monogenic (Mendelian) disorders (such as cystic 
fibrosis). The genetic dissection of inherited traits which lead to increased 
susceptibility to these multifactorial diseases will be invaluable for their prevention 
and treatment. However, identification of genes underlying complex traits is 
inherently more difficult than in a monogenic disorder, where one mutated gene leads 
to disease. This is because in a complex trait the disease susceptibility and 
progression is influenced by multiple genes and modulated by age, gender and 
environmental factors. In addition, the genetic variants that underlie complex traits 
are likely to be present in both affected and unaffected individuals; to be associated 
with relatively modest increases in individual risk; and to interact in a non-finear way 
with other susceptibility factors contributing to disease. Falconer and Mackay 
(Falconer and Mackay 1996) extended this theory by postulating a threshold of risk 
whereby the inheritance of multiple susceptibility genes puts Individuals above the 
mean risk of the population, with a proportion of individuals exceeding the threshold 
and developing disease. 
Complex trait susceptibility genes have many influences which confound their genetic 
dissection including; genetic heterogeneity, epistasis, low penetrance, variable 
expression and pleiotropy (Lander and Schork 1994; Risch 2000). Genetic 
heterogeneity can be divided into locus and allelic heterogeneity. Locus 
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heterogeneity means that the disease may be related to multiple genes at different 
locations in the genome, each acting independently to increase or decrease 
susceptibility to disease. Allelic heterogeneity occurs when different alleles of the 
same gene act on disease susceptibility and this can also occur in monogenic 
disorders. Epistasis refers to the interactions between genes which leads to a greater 
or lesser phenotypic effect than expected from the sum of the effects any of the genes 
individually. Penetrance describes the extent to which the phenotype of a gene is 
expressed. Low penetrance, though difficult to estimate in a complex trait since it 
requires knowledge of potential genes and environmental factors; occurs when the 
disease phenotype is not expressed even though the disease causing allele is present. 
Plejotropy occurs when a single gene mutation results in multiple phenotypic effects 
which often appear unrelated. In addition, apparent disease in some individuals or 
families may be due to the presence of phenocopies; that is environmentally produced 
phenotypes that mimic genetically produced phenotypes. The interaction between 
disease genes and environment can also occur so that in a particular environment a 
gene carrier may be spared development of the disease entirely. 
1.1.1 Identifying complex trait genes 
Methods for mapping and identifying complex trait susceptibility genes fall broadly 
into two categories: either candidate gene identification or a genome wide screen 
(also 
called quantitative trait analysis) but ultimately all result in identification and study of 
a candidate gene. The traditional candidate gene approach 
is carried out using 
knowledge of the biology of known genes and testing of allele 
frequencies in these 
genes in case versus control association studies. 
Quantitative trait analysis originally 
used linkage analysis in pedigrees to 
identify regions of the genome associated with 
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disease and have more recently utilised whole genome tests of association with 
genome wide linkage disequilibrium. A genome wide screen followed by fine 
mapping of candidate genes can provide the most powerful method to detect genes for 
a particular disease. In this case the genomic screen is perforined first to identify 
regions of the genome potentially containing susceptibility genes. Once these regions 
are identified, candidate genes in these areas can be preferentially investigated. This 
positional cloning approach successfully identified the apollpoprotein E4 allele as an 
Alzheimer's disease gene (Pericak-Vance et al., 199 1; Saunders et al., 1993) as one of 
the first examples of a complex trait disease gene. 
1.1.1.1 Candidate gene approach 
Candidate gene studies use knowledge of the biology and pathophysiology of a 
disease to enable potential candidates to be selected based on their known or 
presumed biological function. These selected genes are analysed to detect 
polymorphisms (or alleles) which are then tested for association with disease; that is 
does one allele occur more frequently in patients than in normal controls. Historically 
this process required vast amounts of sequencing firstly to detect polymorphisms and 
then genotyping to detennine if they are disease associated which was laborious and 
time consuming and often led to results which were difficult to interpret (Hirschhorn 
and Altshuler 2002). However with the completion of the human genome and 
availability of a wealth of single nucleotide polymorphism (SNP) 
data and the 
HapMap project (Hirschhorn and Daly 2005; Morton 2005) SNPs can be identified, 
in 
silico, and tested for association with disease. The improved sequence and 
SNP data 
have made it easier and more cost effective to pursue this type of approach. 
In 
addition, the candidate gene approach can 
be highly successful when readily 
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identifiable genes are known to be associated with variation in biologically relevant 
processes that have been well characterised. 
1.1.1.2 Genome wide screen - QTL analysis 
The main alternative to the candidate gene approach is to carry out genome wide 
screens to identify quantitative trait loci (QTL); regions of the genome which 
contribute to disease. Polymorphic genetic markers spanning the entire genome, at 
preferentially no more than I OcM intervals, are tested for linkage to the phenotype. 
Traditionally microsatellites, which are simple short repeats of mono-, di-, tri- or 
tetra-nucleotide repeats that are scattered in non-coding DNA have been the genetic 
markers of choice. These highly polymorphic repeats can be easily genotyped using 
PCR. However due to the availability of increasing amounts of SNP data the genetic 
maps are becoming more dense and this allows the linked regions of the genome to be 
more closely defined. For this type of analysis to succeed the flanking markers and 
the disease gene must co-segregate (be inherited together) in subjects with the disease 
more frequently than expected by chance or in control subjects. 
1.1.1.3 Linkage Analysis and Association Studies 
Both the candidate gene and QTL analyses utifise linkage analysis and association 
studies. Linkage is a genetic relationship between loci (eg flanking markers and 
disease gene) while association is a statistical observation of a relationship between 
alleles and/or phenotypes. Linkage occurs when alleles from two or more genes are 
coinherited, the closer alleles are genetically the more often they will 
be Inherited 
together. Linkage disequilibrium occurs when the combinations of alleles (or markers 
and disease) occur more or less frequently in a population than would 
be expected 
based on the frequencies of the individual alleles. 
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Linkage analysis measures the co-segregation of markers and phenotype to identify 
regions of the genome which influence a trait. In human complex traits non- 
parametric approaches to linkage analysis are more frequently used as they are model 
free and thus more powerful. These methods identify the sharing of alleles identical 
by descent (1131)) or identical by state (IBS) at marker loci in families. The principle 
behind linkage analysis is that two relatives affected with the same disease will share 
alleles IBD near the disease gene(s) more often than expected under the random 
segregation of alleles. 
Association studies, in a simple description, assess whether common allelic variants 
occur together more often than expected by chance. The goal of these studies is to 
find linkage disequilibrium (allefic association) between markers and the disease. 
Linkage disequilibrium is a function of the distance between the marker and the 
disease gene and the genetic history of the population under study and is variable at 
different locations in the genome. 
Linkage and association are complementary to each other and a strategy often 
employed is to carry out linkage analysis across the genome to locallse a candidate 
region and then narrow this region by linkage disequilibrium mapping and perform 
association studies on polymorphisms in individual genes in significant regions. 
In comparison to monogenic disease, and taking into consideration the prevalence of 
complex traits, relatively few underlying genes have been positionally cloned. One of 
the first examples, ApoE4, was mentioned in Section 1.1.1.2 and at least two 
susceptibility genes have been identified in type 2 diabetes, peroxisome proliferator- 
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activated receptor-gamma (PPARy) and CALPAIN-10. A common PPAR)Iallele is 
associated with a decreased risk (Altshuler et al. 2000) while CALPAIN-10 showed 
association with type 2 diabetes in both Mexican Americans and a Finnish population 
(Horikawa et al. 2000). 
The recent advances in genome resources such as availability of annotated sequences 
and databases, fo r example ensembl (www. ensembl. org) and NCBI 
(www. ncbi. nlm. mh. gov), with the development of technologies such as DNA 
microarrays for the global analysis of gene expression have started to facilitate and 
expedite the identification of complex trait genes (Glazier et al. 2002; Farrall 2004; 
Darvasi 2005; Peltonen et al. 2006; Wu and Lin 2006). 
1.2 Metabolic Syndrome, Cardiovascular Disease and Type 2 
Diabetes 
Cardiovascular diseases (CVD), such as coronary artery disease or atherosclerosis, 
and type 2 diabetes (T2D) often result from the complex interaction of environmental 
and genetic factors and are the major cause of morbidity and mortality in westernised 
societies. The occurrence of T2D and CVD are detennined by multiple risk factors 
including hypertension, insulin resistance, dyslipidemia and obesity, which tend to 
cluster together in individuals more frequently than expected by chance (Reaven 
1988a; Reaven 1993). For example, as many as 50% of patients with essential 
hypertension are also found to be insulin resistant (i. e. have impaired insulin action on 
glucose and fat metabolism) leading to an increased risk of cardiovascular disease. 
This clustering of risk factors has been drawn together under the term Metabolic 
Syndrome and is thought to affect 15-25% of people in industriallsed countries 
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(Alberti and Zimmet 1998; 2002). Metabolic syndrome is associated with a 2-4 fold 
increase in CVD morbidity and mortality (Isomaa et al. 2001; Lakka et al. 2002)and 
5-9 fold increase in developing T2D (Balkau et a]. 2003; Sattar et al. 2003). The 
increasing prevalence of metabolic syndrome is due to the dramati III it ic rise in obesity, i 
worsens with age and often culminates in T2D if not CVD. Environmental and other 
factors that augment the primary risk of developing these highly prevalent disorders 
include age, race, sex, diet, and cigarette smoking (Thompson and Wilson 1992). 
There are different sets of criteria to define the metabolic syndrome and they are not 
totally concordant. The World Health Organisation (WHO) definition requires the 
patient to be insulin resistant or have impaired glucose tolerance and at least 2 other 
risk factors from hypertension, dyslipidaemia, obesity and i-nicoalbuminuria (Alberti 
and Zirnmet 1998). The other main criteria are set out by the Adult Treatment Panel 
III and define metabolic syndrome as having any 3 of the following: abdominal 
obesity, atherogenic dyslipidemia, high blood pressure, glucose intolerance and 
prothrombic and proinflarnatory states (2002). 
Many cardiovascular diseases are multifactorial, resulting fi-om the complex 
interaction of environmental and genetic factors. Many of the genetic variants 
predisposing to cardiovascular disease have been proposed to be common in a 
it normal" population (Todd 2001). The simultaneous presence of several predisposing 
rnmor risk alleles, occasionally accompanied by more major, highly deleterious ones, 
may lead to the addition or multiplication of deleterious allelic effects on the 
phenotype. This constitutes an individual "risk allele accumulation", which translates 
into a high individual cardiovascular risk. 
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Identifying genes that underlie risk factors for metabolic syndrome will allow a better 
understanding and development of new treatments which would decrease the health 
burden of these diseases. Following is a discussion of some of the risk factors and the 
underlying genetics that have been elucidated. The risk factors themselves are 
complex traits and therefore also under multigenic and environmental control. 
Hypertension 
Several decades of population research from the North American Framingham Study 
and elsewhere have demonstrated that elevated systemic blood pressure 
(hypertension) is a common and powerful contributor to the i-najor cardiovascular 
diseases associated with accelerated atherogenes's (Kannel 2000). 
Hypertension has been defined by the WHO and the Intemational Society of 
Hypertension as a systolic blood pressure exceeding 140 mm Hg and diastolic 
pressure in excess of 90 nu-n Hg. Although these criteria are soinewhat arbitrary, 
Professor Geoffrey Rose suggested that the best clinical definition of hypertension 
should be "the level of blood pressure above which the benefits .... of action exceed 
those of inaction" (Rose 1980). 
Hypertension can be divided into two categories, primary (or essential) and secondary 
hypertension. Secondary hypertension refers to all cases of hypertension with a 
known cause (either as part of a syndrome or monogenic disorder) and renal disease 
accounts for over 80% of cases. Essential hypertension has no single identifiable 
cause and accounts for over 95% of all hypertension (Sharma et al. 2000). In essential 
hypertension, cardiac output is initially normal and elevated blood pressure is 
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maintained by an increased peripheral resistance in the small arteries and arterioles. 
This increased peripheral resistance is due to structural changes in the vasculature, 
such as narrowing of the arterioles caused by constriction, growth, and proliferation of 
arteriolar smooth muscle cells (Beevers and MacGregor 1999). Patients with essential 
hypertension are also prone to developing atherosclerosis due to lipid-rich deposits 
and inflammation in the arterial wall of cerebral and coronary arteries. In response to 
the increase in peripheral resistance, there is an increased left ventricular load on the 
heart in order to maintain stroke volume and therefore cardiac output. This increased 
load on the heart can result in the development of left vei-itricular hyperti-ophy where 
the heart is increased in size. Ultimately, the function of this chamber deteriorates, 
the cavity dilates, and the symptoms and signs of heart failure appear. 
Pickering first proposed that essential hypertension was multifactorial, with 
hypertensive subjects inheriting an aggregate of hypertension-determining genes 
(Pickering 1961). As stated in Section 1.2, within individual patients, hypertension 
often clusters with other risk factors for cardiovascular disease such as 
hyperlipidaemia, obesity, glucose intolerance and insulin resistance (Reaven 1988a). 
However, the association of hypertension with these metabolic abnormalities is not 
uniform and the mechanisms responsible for these associations remain speculative. 
For example, hyperinsulinaemia has been shown to promote sodium and water 
retention (DeFronzo et al. 1975; Baum 1987) and to stimulate the sympathetic 
nervous system (Reaven et al. 1996). However, studies in patients witb insulinomas 
show that isolated hyperinsulinaemia is not alone sufficient to cause hypertension 
(Sawicki et al. 1992). 
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Blood pressure must be tightly regulated to permit uninterrupted perfusion of all vital 
organs and is determined by cardiac output and vascular resistance to blood flow. 
This simple definition belies the integrated actions of the cardiovascular, renal, neural 
and endocrine systems in the regulation of blood pressure. Included in these systems 
are baroreceptors that sense acute changes in pressure in vessels; natriuretic pept'des 
produced by the brain and heart in response to increased pressure in these organs; the 
renin-angiotensin-aldosterone system, which influences vascular volume homeostasis 
and vascular tone; the kinin-kallikrem system, which affects vascular tone and renal 
salt handling; the adrenergic receptor system which influences heart rate, cardiac 
contraction, and vascular tone; and factors produced by blood vessels that cause 
vasodilation, such as nitric oxide, or contraction, such as endothelin. 
The genetics of hypertension have been studied and estimates from epidemiological 
ies suggest that between 30-50% of the blood pressure variance in the normal stud' I 
population can be accounted for by genetic differences (Hingorini 2000). Race is an 
important determinant of blood pressure, for example, in the US, African Americans 
tend to bave bigher levels of blood pressure than non- African Americans, and overall 
hypertension-related mortality rates are higher among African Americans (Gillum 
1996). There are also examples taken from non inclustrialised populations where low 
blood pressure is more common, such as the Yanomarno Indians in the Amazon 
(Oliver et al. 1975) and in a study of bushmen in Botswana it was observed that blood 
pressure tended to fall with age (Truswell et al. 1972). Similar observations have 
been made in the Xhosa people of South Africa (Sever et al. 1980) and inhabitants of 
the Solomon Islands (Page et a]. 1974). Therefore, care must be taken when selecting 
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individuals for studying hypertension as the genetic effects vary from population to 
population and this will affect results of a genome screen. 
An environmental influence on blood pressure which has been considered is salt 
intake; possibly in light of the fact that all the acqui I ired and monogenic forms of 
hypertension alter blood pressure by changing renal salt balance (Lifton et al. 2001). 
Epidemiological studies demonstrate that the amount of salt consumed In different 
communities is a major factor in determining blood pressure differences between 
these communities (MacGregor 1985; Elliott et al. 1996). The relationship between 
sodium intake and sodium excretion is of major importance in hypertension as it is 
this mechanism that determines extracellular volume. It has long been recogi-iised that 
total-body sodium and water balance is regulated in part by renal arterial perfusion 
pressure (Starling 1909). Guyton proposed that blood pressure and sodium 
homeostasis are related through the mechanism of pressure natriuresis i. e. when renal 
arterial perfusion pressure increases, renal sodium output increases and blood volume 
contracts by an amount sufficient to return arterial blood pressure to its baseline 
(Guyton et a]. 1972). Several other factors such as alcohol intake, nutrition affecting 
blood lipids and stress have been shown to influence blood pressure (Timio et al. 
1997; Kannel 2000). 
In most populations, both systolic and diastolic blood pressure exhibit a continuous 
unimodal distribution, a feature which is characteristic of a complex trait. Evidence 
suggests that while environmental factors exert a major influence on the average level 
of blood pressure in any given population, it is genetic factors which determine the 
position of an individual within the blood pressure distribution (Harrap 1994). 
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Candidate gene and genome wide screens have both been carried out to identify genes 
involved in hypertension. Candidate gene studies focussed on the molecules with a 
known involvement in the vasoconstriction and dilation of blood vessels and in the 
renin-angiotensin system which plays a central role In blood pressure regulation, 
where it functions to regulate sodium homeostasis and modulate vascular tone and 
structure (Sealey and Laragh 1990). One example of a candidate gene for 
hypertension is angiotensinogen (AGT) which was first studied because a strong 
correlation was detected between AGT concentration and blood pressure (Walker et 
al. 1979). The role of AGT in hypertension has been extensively studied and is still 
unclear; a recent review (Dickson and Sigmund 2006) summaries the 500 or more 
association studies carried out and concludes that some variants in this gene are likely 
to confer a small risk for hypertension. A mouse model featuring increased 
expression of the angiotensinogen gene exists and demonstrates elevated blood 
pressure which supports this genes involvement in development of hypertension 
(Takahashi and Smithies 1999). 
The angiolensin convei-0 . ng enz. vine (ACE) is another widely studied human 
hypertension candidate gene and certain allefic genotypes do associate with disease; 
however the results remain largely equivocal (Lindpaintner et al. 1996; Montgomery 
et al. 1997). 
There have been several genome wide scans carried out for essential hypertension 
which pinpoint many regions of the genome, some of which contain good candidate 
genes. This will be discussed further in Cbapter 5 where all 
human QTL from 
genome wide screens have been gathered and used 
in a comparative mapping study. 
25. 
1.2.2 Insulin Resistance 
Insulin resistance can be operationally defined as a state when insulin action on both 
glucose and fat metabolism is impaired. This can be detected in an individual tissue 
or at the whole body level and is often accompanied by compensatory 
hyperinsulinaernia and hyperglycaemia. Insulin resistance is one of the central 
metabolic defects of type 2 diabetes and predisposes an individual to other features of 
the metabolic syndrome such as dyslipidemia and hypertension (Reaven 1995). In 
addition, insulin resistance is a common accompaniment of obesity and can also be 
secondary to it. Metabolic studies of type 2 diabetes, familial combined 
hyperliplaernia (FCHL), hypertension and obesity have shown that insulin action is 
defective on both glucose and fatty acid metabolism in these conditions (Chen et al. 
1987; Ferrannini et al. 1987; Aitman et al. 1997b; Kooner et al. 1998). 
Catecholamine-mediated lipolysis, the release of fatty acids from fat stores, is also 
defective in some of these disorders (Reynisdottir et a]. 1994; Reynisdottir et al. 1995; 
Bougneres et a]. 1997). These metabolic studies have suggested the presence of a 
primary defect in insulin and catecholamine action at the level of the adipocyte in 
several of the insulin resistance syndromes (Arner 1997; Aitman et a]. 1997a). 
Rare monogenic forms of insulin resistance occur and in most cases have been 
attributed to mutations in the insulin receptor gene including homologous deletions, 
mutations in the tyrosine kinase domain and nonsense mutations resulting in truncated 
protein (Wertheimer et al. 1993; Desbois-Mouthon et al. 1996; Jospe et al. 1996). 
However, the common forms of insulin resistance are believed to be under the 
influence of many genetic and environmental factors. As with hypertension, 
candidate gene investigations and genome screens have been carried out and again the 
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genome screens are presented in Chapter 5. One candidate gene that has been 
examined is the insulin receptor which, as outlined above, accounts for many 
monogenic fon-ns of insulin resistance and is thought to account for <2% of complex 
insulin resistance and T2D (Taylor and Moller 1993). 
Insulin receptor substrate I(IRSI) binds to the phosphotyrosines on the insulin 
receptor and is itself phosphorylated and activated following binding of insulin to the 
insulin receptor. This gene was therefore identified and studied as another good 
candidate and a Gly 972 --- >Arg polymorphism confers lower insulin sensitivity to obese 
carriers (Clausen et al. 1995). This polyi-norphism is more prevalent In patients within 
the top 2 percentile for insulin resistance and dyslipidernia in Caucasian T2D subjects 
(Zhang et al. 1996). A Pro 12 -->Ala polymorphism has been investigated in another 
candidate gene PPAR)1. PPAR)/, is a transcription factor which regulates adipocyte 
differentiation (Tontonoz et a]. 1994) and plays an important role in lipid metabolism, 
glucose homeostasis, insulin sensitivity, obesity, diabetes, foam cell formation and 
atherogenesis and it is the target molecule for the thiazolidinedione group of drugs 
which enhance insulin sensitivity (Lehmann et al. 1995). It was hypothesised that the 
Pro 12 ->Ala substitution may cause a reduction in the transcriptional activity of PPAR)l 
and thus may be associated with increased insulin sensitivity and decreased risk of 
type 2 diabetes (Hara et al. 2000). Another study failed to confirm this but agrees that 
genetic variability of PPAR)l affects body weight control and lipid homeostasis in 
humans (Meirhaeghe et al. 2000). The genetics of type 2 diabetes has been reviewed 
recently and the above are just a few examples of studies carried out (McCarthy 
2004). 
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1.2.3 Dyslipidaemia 
Lipoprotem particles transport lipids, cholesterol, triglycerides and phospholipids 
around the body in the bloodstream. Serum cholesterol and triglyceride levels are 
determined by several metabolic pathways, ligands and receptors and involve several 
tissues including the liver, adipose, the small intestine and skeletal muscle. 
Chylomicrons transport dietary lipids like triglycerides from the intestines to the liver. 
Very low density lipoproteins (VLDL), low density lipoproteins (LDL) and high 
density lipoproteins (HDL) transport endogenous lipids. VLDL and LDL transport 
cholesterol from the liver to the tissues and LDL is considered 'bad' cholesterol as it 
can build up which leads to narrowing and inflammation (clogging) of the arteries 
(atherosclerosis). HDL transports excess cholesterol from tissues back to the liver for 
removal; this is a very important mechanism as tissues do not have a mechanism of 
breaking down cholesterol. 
Genetic linkage and sequence studies of the lipoprotein particles have elucidated 
mutations and often the mechanism of action which leads to dysfunction. This led to 
the development of statins, (HMG-CoA-reductase inhibitors) which are lipid lowering 
drugs. Many of the initial insights into disorders of lipId metabolism came from the 
study of monogenic hypercholesterolaernias. Familial hypercholesterolaemia 
(FH) is 
the most common form (Goldstein et al. 1973); patients have high LDL cholesterol 
caused by mutation(s) in the LDL receptor gene. Other monogenic 
forms detected 
mutations in the apoA], apoB-100, PSCK9 and ABCAI genes. 
The most common 
inherited form of hyperlipidaemia, FCHL, 
is found in approximately 30% of 
myocardial intarction survivors and may affect up to one in 
50 of the general 
population (Goldstein et al. 1973; 1998). FCHL 
has hypertriglyceridaernia associated 
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with hypercholesterolaernia and is most often due to an increase in VLDL and LDL. 
The lipid abnon-nalities seen in FCHL may occur as part of the metabolic syndrome 
however patients with FCHL must have a blood relative with primary 
hyperlipidaemia. At least 3 chromosomal locations have been investigated in multiple 
genome wide scans for candidate genes underlying this disease and the LCAT gene 
and APOAlIC31,44IA5 gene cluster have been shown to be important in FCHL 
(Shoulders et al. 2004). 
1.2.4 Obesity 
Obesity, particularly central (abdominal) obesity is a major and important feature of 
the metabolic syndrome and is characterised by an increased fat mass which occurs 
when the intake of food exceeds the energy requirement of the body (Splegelman and 
Flier 1996). The dramatic escalation of obesity in the western world in the past 30 
years is due, at least in part, to an increasingly sedentary lifestyle and dietary changes 
including increase in dietary fat and carbohydrate. 
Abdominal obesity, as opposed to whole body obesity, is proposed to be a better 
indicator of CVD risk overall (Rinu-n et al. 1995; Lakka et al. 2002), therefore it has 
been suggested that waist circumference or waist to hip ratio is a better measure of the 
cardiovascular complications of obesity than body mass index (BMI) (Carey et a]. 
1996). The components of the metabolic syndrome occur more frequently in obese 
people but this is thought not to be due to the obesity per se, but to the fact that 
increased adiposity increases the likelihood that an individual will be Insulin resistant 
(Abbasi et al. 2002; McLaughlin et al. 2003). An increase in free fatty acids (which 
make up triglycerides) leads to hyperinsulinaemia as there is a reduction in hepatic 
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insulin sensitivity which results in increased glucose output and decreased I in 
clearance. Availability of more fatty acids also provides substrates for triglyceride 
synthesis which results in hypertriglycendaemia and lastly may also inhibit glucose 
uptake by skeletal muscle. 
Adipose tissue comprises the body's largest endocrine organ as it not only stores 
excess body energy in the form of fat but also secretes many systemically functioning 
adipokines, for example TNF(x, resistin and adiponectin. Clinical studies have 
demonstrated that a low blood level of adiponectin is associated with atherosclerotic 
CVD, T2D, hypertension and dyslipidemia (Zoccali et al. 2002; Pischon et al. 2004; 
Schulze et al. 2005). Also genetic analyses of SNPs within this gene have identified 
some variants which may determine plasma concentration or affect the ability of 
adiponectin to multimerise (Kondo et a]. 2002; Sturnvoll et a]. 2002; Kishida et al. 
2003; Ohashi et al. 2004). 
Recent reviews of the genetics of obesity (Bell et a]. 2005) present the overview of the 
outcomes of the many genome wide screens for obesity carried OL)t in humans. 
1.3 Animal models 
The features of the metabolic syndrome and thus CVD and T2D cluster together and 
can cause and/or affect each other. This is common in genetically complex traits, that 
is, it is difficult to separate out the different parts of the trait to enable the genetic 
dissection of the disease (Merikangas and Risch 2003). Animal models of 
human 
metabolic and cardiovascular disease have 
been widely used to elucidate the 
mechanisms underlying these disorders, since they 
have several advantages over 
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human studies for gene identification. Firstly, the use of inbred strains eliminates 
genetic heterogeneity between affected individuals thereby limiting the number of 
alleles involved to those that differ between strains. Secondly, rare alleles can be 
fixed in inbred strains by a programme of selective breeding. Thirdly, breeding 
protocols can be manipulated to generate experimental crosses that are most 
informative for linkage analysis. Fourthly, all offspring from many crosses can be 
combined into a single large group for analysis as a single pedigree (Risch 2000). 
Fifthly, very detailed phenotyping not possible in hurnans such as terminal 
phenotyping can be carried out and finally the environment can be controlled which 
minimises or eliminates the variability between individual animals. All of the above 
make linkage analysis more practicable in animal models and result M more robust 
QTL with higher statistical significance. However positional cloning of the genes 
underlying these QTL is still a significant challenge, mainly because of the lack of a 
one-to-one correspondence between genotype and phenotype. 
1.3.1 Rat Models of Metabolic Syndrome 
Inbred rat strams have been studied for over 50 years creating a wealth of genetic and 
phenotypic data for use in studies of the onset, development and progression of tl 
complex diseases. There is an immense amount of literature available about the rat as 
a model organism including information on physiological mechanisms including 
blood pressure regulation, making this model species particularly appropriate for 
disease-based research. For example, between 1975 and 2006 PubMed lists over 
14,700 publications on the spontaneously hypertensive rat, the model used in this 
thesis. The publication of the rat genome sequence has greatly ameliorated the 
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previous paucity of genome sequence data in the rat compared to the mouse and 
provided valuable insights into mammalian evolution (Gibbs et al. 2004). 
One drawback of using rat, or other rodent models, is that they generally do not 
develop atherosclerosis, that is the atheroma of the coronary arteries which leads to 
atherosclerotic plaque rupture, and MI and this is the main pathophysiological 
endpoint associated with coronary artery disease (CAD) (Rekhter 2002; Rekhter 
2002). This is due to the fact that unlike humans, rats and mice have a naturally high 
level of HDL, the molecule which clears cholesterol from the body by transporting it 
back to the liver, along with relatively low levels of the atherogenic lipoprotein LDL. 
This section outlines a number of animal models which may be amenable for study as 
models of the metabolic syndrome. 
1.3.1.1 Dahl Salt Sensitive Rat 
The Dahl salt sensitive (S) rat was generated from a colony of outbred Sprague- 
Dawley rats selected for sensitivity to salt-induced hypertensIOD (Dahl et a]. 1962-, 
Rapp et al. 1984). A salt-resistant strain (R) was also maintained. Both strains were 
bred on the basis of their blood pressure after being fed a high salt (8% NaCl) diet. 
Dahl S rats develop severe hypertension and marked vascular and renal lesions after 
3-4 weeks on a high salt diet and all die within 8 weeks (Rapp and Dene 1985). The 
strain is maintained on a low salt diet (0.3% NaCI) and although they develop marked 
hypertension, there is a slower rise in blood pressure (Rapp and Dene 1985). Kidney 
transplantation experiments between Dahl S and Dahl R rats suggest that the 
kidney 
plays a central role in blood pressure regulation 
in these strains (Dahl and Heine 
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1975). At least 14 QTL regions influencing blood pressure have been identified in 
Dahl S rats (Garrett et al. 1998; Rapp 2000). 
1.3.1.2 Fructose fed rats 
Environmental manipulations have been shown to induce both increased blood 
pressure and insulin resistance. The best example of this is the fructose-fed rat. To 
determine if hypertension could be induced in normal rats by feeding them a fructose- 
enriched diet, Sprague Dawley rats were fed a diet containing 66% fructose as a 
percentage of total calories for 2 weeks (Hwang et a]. 1987). Systolic blood pressure 
increased in the fructose-fed rats, with no change in the control group (Hwang et al. 
1987). In addition, hyperinsulinaemia and hypertriglyceridernia were associated Nvith 
hypertension in this model (Hwang et a]. 1987). Fructose fed rats are now a well 
established, environmentally induced model of increased blood pressure and insulin 
resistance. 
1.3.1.3 Lyon hypertensive rat 
Lyon hypertensive (LH) rats were bred from a colony of Sprague-Dawley rats 
selected for high systolic blood pressure (Vincent et al. 1984). A non-notensive 
control (LN) and a hypotensive control (LL) were also bred at the same time (Vincent 
et al. 1984). This strain exhibits mild hypertension, increased body weight, increased 
plasma triglycerides and insulin when compared to the LN controls (Vincent et al. 
1993). 
1.3.1.4 Spontaneously hypertensive rat 
The spontaneously hypertensive rat (SHR) was selectively bred for high blood 
pressure in the absence of dietary or environmental stimuli 
from outbred Wistar 
Kyoto rats. A male with rmld hypertension was mated with a female with 
high blood 
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pressure followed by repeated brother x sister mating with continued selection for 
high blood pressure (Okamoto et al. 1972; Yamori 1984). SHR has been widely 
studied as a model of both hypertension (Yamori 1984; Pravenec et al. 1995; Munroe 
and Caulfield 2000; Rapp 2000) and insulin resistance (Reaven et al. 1989b; Aitman 
et al. 1998; Sechi 1999). Defective insulin-mediated glucose uptake has been 
observed in isolated adipocytes and at the whole body level (Reaven et al. 1989b; 
Hulman et al. 1991; Hulman et al. 1993). A reduction in sensitivity to catecholarnine 
action has been observed in isolated adipocytes (Chiappe de Cingolani 1988). SHR 
also show hypertriglyceridemia, hyperinsulinaemia (Qu and Donnelly 1997) and 
abdominal obesity (Aitman et al. 1997b). 
An inbred Wistar Kyoto strain, WKY, is often used as a normotensive control 
although its suitability has been questioned as it differs from SHR at 50% of genetic 
marker loci (St Lezin et al. 1992). Additional normotensive strains, for example 
Brown Norway (BN), are often used in comparative studies (Rapp 2000) including 
the work presented in this thesis. The SHR strain will be discussed in more detail in 
Section 1.4. 
1.3.1.5 Stroke prone spontaneously hypertensive rat 
Prior to SHR becoming fully inbred, a substrain with exceptionally high blood 
pressure was found to be more susceptible to stroke than other SHR substrains. 
This 
substrain was subsequently selectively bred for a high incidence of stroke 
[Okamoto, 
1974]. Male systolic blood pressure is 190-250 mm Hg in SHRSP compared with 
125-140 nim Hg in the nonnotensive control WKY (Jacob et al. 
1991). Eighty-two 
percent of male SHRSP over 100 days of age and 
58% of females over 150 days have 
cerebral haemorrhage or infarction (Yamori 
1984). QTL regions conferring 
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sensitivity to stroke have been identified on chromosomes 1,4 and 5 In an SHRSP x 
SHR cross (Rubattu et al. 1996; Jeffs et al. 1997), while at least nine blood pressure 
QTLs have been identified in SHRSP x WKY crosses (Rapp 2000). This strain also 
exhibits insulin resistance with abnormal insulin action on glucose and fatty acid 
metabolism which is distinct from the Cd36 deficiency seen in SHR (Collison et a]. 
2000). 
1.4 The Spontaneously Hypertensive Rat as a Model of Metabolic 
Syndrome 
The spontaneously hypertensive rat (SHR) is a widely studied model of Metabolic 
Syndrome. In SHR, as in many humans with hypertension, the hypertensive 
phenotype clusters with metabolic traits such as insulin resistance and dyslipiderma, 
which are associated with increased risk of cardiovascular disease. As mentioned in 
Section 1.3.1.4, SHR was selectively bred for high blood pressure from outbred 
Wistar Kyoto rats and has been shown to have both hypertension and insulin 
resistance (Yamori 1984; Reaven et a]. 1989b; Pravenec et al. 1995). Within this 
strain insulin resistance has been observed at the whole body level and in isolated 
adipocytes (Reaven et al. 1989b; Hulman et al. 1991, Hulman et al. 1993; Rao 1993; 
Patemostro et al. 1995). Also, a reduction in the sensitivity of adipocytes to 
catecholamine action on the promotion of 11polysis has been observed (Nelson et al. 
1987; Chiappe de Cingolam 1988; Reaven et al. 1989b). These adipocyte phenotypes 
have also been observed in FCHL, Metabolic Syndrome and upper body obesity 
(Reynisdottir et al. 1994; Reynisdottir et al. 1995). These cellular defects in SHR 
adipocytes suggest a similarly altered fat cell metabolism to that seen in human 
insulin resistance. 
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1.4.1 Hypertension in SHR 
The SHR strain was bred with continuous selection for high blood pressure over 5 
generations and develops hypertension spontaneously, without dietary or 
environmental stimuli, at the age of 5-15 weeks (Yamori 1984). Systolic blood 
pressure reaches 170 mm Hg by 10 weeks of age (Tanase et al. 1982) and plateaus at 
approx. 200 mm Hg at 20-28 weeks (Yamori 1984). Hypertension in SHR is 
associated with increased peripheral vascular resistance and a non-nal cardiac output 
(Yamori 1984) while levels of plasma renin and angiotensin 11 are not elevated 
(Campbell et al. 1995). SHR rats have fewer glomeruli than WKY rats which results 
in a reduced glomerular volume consistent with the view that the kidney plays an 
important role in hypertension. As in humans, environmental factors including excess 
so iurn ntake, stress (Kvetnansky et al. 1979) and social alterations (Horle et al. 
1991) have been shown to influence development of hypertension in SHR. 
1.4.2 Insulin resistance and dyslipidemia in SHR 
Initial comparisons of insulin metabolism in SHR and control rats using an oral 
glucose tolerance test showed indirect evidence of resistance to insulin-mediated 
glucose uptake in SHR (Mondon and Reaven 1988). The presence of insulin 
resistance and hyperinsulinaemia in SHR led to direct experiments to measure insulin- 
mediated glucose uptake and the ability of insulin to suppress catecholamine- 
mediated lipolysis in isolated adipocytes (Reaven et al. 1989b). Adipocytes were 
isolated from SHR rats, derived from the NIH colony, and non-notensive Wistar 
Kyoto (WKY) control rats. Glucose transport was measured in isolated adipocytes 
incubated in the presence of differing concentrations of insulin and r 
14_C] D-glucose. 
Lipolysis was also measured in isolated adipocytes incubated in the presence of 
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isoproterenol (or isoprenaline) and increasing concentrations of insulin. Glucose 
uptake was significantly lower in adipocytes from SHR rats when incubated in the 
absence of insulin and at every insulin concentration (Reaven et al. 1989b). 
Catecholamine-mediated lipolysis was lower in adipocytes isolated from SHR both iii 
the absence of insulin and at every insulin concentration; however, the relative ability 
of insulin to suppress lipolysis was increased in adipocytes from SHR (Reaven et al. 
1989b). 
This work demonstrated insulin resistance in SHR adipocytes. Further work also 
showed insulin resistance in cardiac muscle (Patemostro et al. 1995). Measurements 
of basal and insulin-mediated glucose uptake in perfused hearts from SHR and WKY 
by 3 'P NMR spectroscopy showed a 3-fold increase in basal glucose uptake in SHR 
but an 18% decrease in insulin-mediated glucose uptake (Patemostro et al. 1995). 
Insulin resistance has been measured in SHR at the whole body level using the 
euglycaemic-hyperinsulinaemic clamp in conscious and anaesthetised rats (Hulman et 
al. 1991; Hulrnan et al. 1993). Total insulin-mediated glucose uptake was found to be 
significantly lower in SHR than in WKY, indicated by the reduced glucose infusion 
rate required to maintain euglycaemia in SHR (Hulman et al. 1993). 
An important consideration when measuring insulin-mediated glucose uptake during 
clamp studies was raised by Rao (Rao 1993). During euglycaemic clamp studies, 
insulin-mediated glucose uptake and hepatic glucose output was shown not to differ 
significantly between WKY and SHR (Rao 1993). This had led to the suggestion that 
SHR was not insulin resistant (Buchanan et al. 1992). However, steady-state plasma 
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insulin levels in SHR were found to be double that of WKY, indicating that SHR had 
a marked defect in insulin clearance (Rao 1993). Additional studies were performed 
in order to produce equivalent steady-state plasma insulin levels in the two strains 
and, under these conditions; a marked difference was seen in both insulin-mediated 
glucose uptake and insulin-mediated suppression of hepatic glucose output between 
SHR and WKY. SHR was shown to have a 50% reduction in insulin-mediated 
glucose uptake and impaired suppression of hepatic glucose production (Rao 1993). 
Abnon-nalities in lipid metabolism in SHR were observed in the late 1970s (Iritani et 
al. 1977). When comparing SHR to control WKY rats, plasma cholesterol was found 
to be decreased, and plasma triglycerides and free fatty acids were found to be 
increased (Iritani et al. 1977). A study of the responsiveness of isolated adipocytes 
from SHR and WKY to the effect of norepinephrine on lipolysis demonstrated that 
the response was lower in SHR adipocytes compared to WKY, but there was no 
significant change in the basal rate of lipolysis (Chiappe de Cingolani 1988). 
Glucose and fat metabolism have been examined together by assaying insulin and 
catecholamine action in isolated adipocytes from SHR and normotensive WKY rats 
(Aitman et al. 1997b). Reteroperitoneal adipocytes from SHR showed a reduction in 
sensitivity to insulin measured by a reduction In Insulln-medlated glucose uptake and 
a reduction in sensitivity to isoproterenol measured by isoproterenol-mediated non- 
esterified fatty acids (NEFA) secretion (Aitman et al. 1997b). 
SHR also show the hypertnglyceridemia, hyperinsulinaemia and abdominal obesity, 
common phenotypes of human metabolic syndrome. Blood samples 
from SHR and 
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WKY rats were analysed for levels of serum glucose, insulin and triglyceride 
concentrations (Qu and Donnelly 1997). SHR rats were shown to have higher fasting 
insulin, higher triglycerides and higher NEFA concentration (Qu and Donnelly 1997). 
In addition, SHR have been observed to have increased abdominal fat when compared 
to the Brown Norway (BN) normotensive control (Aitman et a]. 1997b). 
1.4.3 SHR QTL for metabolic syndrome 
The genetics of metabolic syndrome, and the underlying risk factors, hypertension, 
insulin resistance and dyslipidemia have been widely studied by genome wide linkage 
screens. As of October 2004 more than 60 QTL for hypertension and metabolic 
phenotypes had been identified in SHR (Rat Genome Database, http: //rgd. mcw. edu), 
with this number being added to all the time. These QTL will be discussed further in 
Chapter 5 and at the time of writing the number in RGD had increased to more than 
200. QTL have also been mapped using a recombinant inbred (RI) strain set that was 
derived from the hypertensive SHR/Ola and the normotensive BN. Lx/Cub (Section 
1.6). 
A review by Rapp (Rapp 2000) collated all the hypertension QTL in the rat, at that 
time 24 QTL across 17 of the 20 autosomes and both sex chromosomes. The virtual 
comparative (VC) map tool at RGD can now be used to visuallse all rat QTL and an 
example of one chromosome is shown in Figure I. I. This demonstrates the increased 
amount of 
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available information and yet still only a handful of QTL genes have been positionally 
cloned. Elucidation of the molecular basis of these QTL in SHR may throw insights 
into the related human disorders; however the underlying genes have yet to be 
identified in most cases. 
1.5 Strategies for analysing QTL in rat models 
Section 1.3 describes the advantages animal models have over human studies for 
disease gene identification in complex traits. In animal models, as in human QTL 
studies, linkage analysis across the whole genome is carried out to identify regions 
which influence the trait of interest. An experimental cross is set up between two 
strains, for example one with hypertension and a nori-noteiisive control. This ineans 
all the animals in the FI generation are heterozygous at all loci for each of the 
progenitor (parent) strains. The F1 generation is intercrossed to produce a large F2 
population and more than 300 animals are required to achieve statistical significance. 
The F2 animals are then phenotyped for quantitative traits, such as blood pressure and 
genotyped across all the markers in the genome to deten-nine which parental alleles 
is/are present at each marker. This is an example of linkage analysis in a segregating 
population. Linkage analysis identifies chrDmosomal regions, containing a gene (or 
genes) influencing complex traits such as blood pressure, that are frequently too large 
for positional cloning. The limiting factors in linkage analysis are the modest effects 
genes often have on the overall phenotype in a complex trait and the limited number 
of chromosomal recombination events that can be observed in segregating populations 
of practical size, e. g. F2 generations (Rapp 2000). Therefore approaches 
have been 
developed either to more precisely map or narrow the interval or to select genes 
from 
within the region based on known relevant biology and or gene expression patterns. 
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1.5.1 Recombinant inbred strains (RI strains) 
Recombinant Inbred (RI) strain panels are one of the most powerful resources 
developed for disease gene mapping in rats and mice (Silver 1995). Like all inbred 
strains, RI strains are fixed to homozygosity at essentially all loci and are therefore 
genetically stable and a renewable resource. Each strain within an RI panel has 
undergone different recombination events during inbreeding and therefore has a 
unique allele distribution throughout the genome consisting of blocks of parental 
alleles, in this case BN and SHR (Figure 1.2). The comparison of this distribution of 
alleles across all the RI strains in a panel generates a unique strain distribution pattern 
(SDP), which can be correlated with a particular phenotype or other genetic markers, 
as can be seen for the hypothetical gene xyz in Figure 1.2. The advantage of RI 
strains is that once developed they are a permanent resource, as genetically identical 
animals can be propagated as required by repeated brother-sister matings. This allows 
the accumulation of phenotype and mapping data over several years or even decades. 
Since all RI strains within an RI panel are derived from the same parental strains they 
are effectively a permanent F2 generation as each strain is a genetic mix of parental 
alleles and therefore a segregating population in terms of linkage information. 
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1.5.2 Congenic strains 
A further advantage of using model systems is the ability to generate congenIc strains. 
In a congenic strain, a specific region of a chromosome Is replaced with the 
corresponding chromosomal region from a different strain. Strain differences on this 
chromosomal segment can therefore be studied in isolation from strain differences on 
other chromosomes. Once a congenic strain is constructed that includes a QTL, 
congenic substrams can be created with smaller and smaller donor fragments to 
locallse the QTL more precisely. Congenic strains have been created for several of 
the QTL identified in SHR. This is a very powerful technique, which facilitates fine 
mapping and increases the likelihood of complex gene identification and one that 
clearly can not be used in human genetics 
1.5.3 Positional candidates 
Subsequent to identification of a chromosomal region containing a gene (or genes) 
influencing the complex trait being studied e. g. blood pressure, biological candidate 
genes in the region can be analyzed for sequence variation between rat strains. The 
variation detected can then be assessed for association with the phenotype and the 
IIIIh causative variant identified. If no known biological candidate exists in the region t en 
analysis of all genes can be carried out. This is facilitated by use of congenic strains 
which significantly reduce the size of a QTL thus lowering the number of genes 
which must be tested and studying the gene expression of the genes to determine if 
they are differentially expressed. 
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1.5.4 Differential gene expression 
It is not uncon-u-non for QTL regions to be as large as 30cM or more, containing many 
hundreds of genes, the majority of which are urtcharacterised and have little sequence 
polymorphism data available. Therefore, an alternative strategy for identifying 
candidate genes is to use the analysis of gene expression in affected and unaffected 
strains. The target gene of interest may be identified by characteristic changes in 
expression level across a series of samples of varying genotype, for example a mutant 
gene may show a reduced expression level in samples with the abnormal allele. The 
availability of expression data may also aid gene identification by revealing pathways 
related to the target gene and thereby facilitating the identification of candidate genes. 
A gene expression study using a microarray-based approach identified around 250 
genes that were differentially expressed between SHR and BN in adipose tissue. One 
gene was also found to have a reduced hybridisation signal in SHR when compared 
with a chromosome 4 congenic strain. This gene was Cd36 and further analysis 
confirmed that this gene underlies the chromosome 4 insulin resistance QTL in SHR 
(Aitman et al. 1999). 
1.6 Generation of the BXH/HXB Recombinant inbred Strains 
During the 1980's SHR (SHR/Ola) was intercrossed with normotensive Brown 
Norway (BN/Lx) rats to develop a panel of BXH/HXB recombinant inbred (RI) 
strains (Pravenec et al. 1989; Printz et al. 2003). To date more than 1000 genetic 
markers have been mapped on this RI panel forming a high-resolution genetic map 
for 
studies in these strains (Pravenec et al. 1996). The framework map contains around 
850 markers with an average distance between markers of 
2.7cM. Over 45 
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independent physiological and metabolic phenotypes have already been mapped 
within this RI panel and new phenotypes are continuously being added. 
Mean arterial pressure and left ventricular heart weight are two of the phenotypes that 
have been measured in this RI strain set (Pravenec et a]. 1995) and QTL for blood 
pressure were found on chromosomes 2,4 and 19. Systolic blood pressure linked to 
chromosome 19, diastolic blood pressure linked to chromosome 2 and mean arterial 
pressure linked to the 116 marker on chromosome 4. For each phenotype, the SHR 
allele was associated with an increase in blood pressure. An additional QTL for left 
ventricular heart weight (corrected for body weight) was identified on chromosome 
17, with the SHR allele associated with a lower left ventricular mass than the BN 
allele (Pravenec et al. 1995). Dyslipidemia was also mapped in the RI strains to 
chromosomes 4,8 and 20 (Bottger et al. 1996). Lipid phenotypes of total cholesterol 
and phosphollpid, VLDL cholesterol and phospholipids, LDL/HDLI cholesterol and 
phosphollpids, IDL cholesterol and pbospholipids and HDL2 phospholipids were 
measured. The SHR/Ola strain exhibited lower levels of total cholesterol and 
phospholipids, lower levels of VLDL cholesterol and phospholipids and higher levels 
of HDL2 phosphollpids than the BN/Lx strain, when both were fed a high fat/high 
cholesterol diet. In addition, association was seen in the RI strains between basal 
levels of HDL2 phospholipids and the 116 marker on rat chromosome 4 (P<0.0005), 
with animals carrying the SHR allele having lower levels of HDL2 phospholipid 
(Bottger et al. 1996). Finally QTL on chromosomes 4,12 and 16 associated with 
defective insulin-mediated glucose uptake were mapped and a significant linkage was 
seen in the RI strains to chromosome 7 for basal glucose uptake (Aitman et al. 
1997b). 
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1.7 Microarray Expression profiling 
1.7.1 DNA microarrays 
DNA microarrays have been developed to analyse the expression of numerous genes 
simultaneously. There are two main types: 1) cDNA clones or their PCR-amplified 
products are spotted on the slide and 2) oligonucleotide sequences representing 
selected genes, are spotted or synthesised on the array. Technologies developed for 
computer chips allow thousands of genes to be spotted on a single slide allowing the 
interrogation of the entire genome in a single experiment. The two types are 
manufactured differently but the experimental analysis principles are very similar 
(Harrington et al. 2000), both involve reverse transcription of RNA fi-orn a cell or 
tissue type and hybridisation of the resultant cDNA or cRNA onto the array. 
Microarrays have been utilised in a number of ways and one of the first successful 
applications to human disease was in the study of cancer classification in acute 
leukaernias for class discovery and class prediction (Golub et a]. 1999). Since the 
1960s, the acute leukaernias have been classified as either acute lymphoblastic 
leukaemia (ALL) or acute myeloid leukaernia (AML) although no single test is 
sufficient for diagnosis. Distinguishing ALL from ANIL is critical for successful 
treatment. The authors identified I 100 genes with an expression pattern that was 
strongly correlated with the AML-ALL class distinction. The expression levels of a 
subset of 50 genes most strongly con-elated with class distinction were used to create 
a class predictor capable of assigning a new sample to one of the two classes. The list 
of informative genes also provided new markers of acute leukaemia subtype. 
The 
class discovery procedure could distinguish between AML and 
ALL without previous 
47. 
knowledge of these classes and identified two subclasses of ALL: T-lineage ALL and 
B-lineage ALL. 
This type of analysis also generates potentially useful data concerning sets of genes 
that are differentially regulated between non-nal and disease cells. This may help 
understand disease pathophysiology and identify other genes that act in the same way, 
or in compensatory pathways, as the primary defect. 
1.7.2 Integrated linkage analysis and gene expression approach to disease gene 
identification 
A novel approach using integrated linkage analysis and gene expression profiling to 
identify genes involved in complex traits was proposed in 2001 (Jansen and Nap 
2001). This strategy, called "genetical geim-nics", uses the heritability of gene 
expression profiles and this bridges the gap between genotype and phenotype since 
transcript abundance is an inten-nediate phenotype between genomic sequence 
variation and phenotype. In this approach gene expression data is treated as a 
quantitative phenotype much as in conventional linkage analysis traits such as blood 
pressure or glucose levels would be treated quantitatively. Microarray based 
expression profiles are generated from all individuals in a segregating population and 
then mapped to the genome by the same methods of linkage analysis used to map 
physiological phenotypes. The BXH/HXB RI panel is an example of a segregating 
population in which replicates can be generated by study of multiple animals with 
identical genotype from within each strain. The example described in Section 1.7.1 
used microarrays and linkage analysis to identify the Cd36 gene and the 
difference of 
the method described here is that this is on a whole genome scale. 
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Just as linkage analysis and mapping of a physiological phenotype results in a QTL 
(or QTLs) for that phenotype, mapping the expression profile of a particular gene onto 
the genorne results in QTL(s) for expression of that gene. The expression profile acts 
as a phenotype and the resulting QTL can be termed an expression QTL (eQTL) 
which is distinct from a physiological QTL or pQTL, where a phenotype such as 
blood pressure is mapped. 
This genetical genomic approach allows the genetic determinants of gene expression 
to be mapped by linkage analysis to discrete regions of the genome and will indicate 
what proportion of the variation in gene expression maps to the same chromosomal 
region as the gene itself (cis-acting eQTL) or to another region of the genome (trans- 
acting eQTL) (Figure 1.3). In the case of a trans-acting eQTL, the region of the 
genome to which the eQTL maps is regulating (ti-ans-regulating region) expression 
and the gene itself is being regulated (Irans-regulated gene). This approach not only 
allows cis and trans-acting factors to be identified but can also be used to identify 
gene-gene interactions and thus pathways can be determined. Cis-acting eQTL are 
caused by genomic sequence variants that reside within or close to the gene while for 
a trans-regulated gene the polymorphism that cause the differential expression will 
reside elsewhere in the genome, at the site of the eQTL (trans-regulating region). 
These eQTL may be considered as postional candidates for previously mapped QTL 
when they reside within a pQTL (Figure 1.3). 
The first study to use this integrated whole genome approach was carried out using a 
simple eukaryote, S. cerevisiae. Brem el al (Brem et al. 2002) performed genetic 
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Figure 1.3 Control of expression QTL (eQTL) 
eQTL are shown in red and genes in black for the hypothetical Xyz and abc genes. A. 
Expression of the xyz gene is linked to the xyz gene itself and is therefore cis-acting, 
while B. the eQTL for gene abc is linked to a different region of the genome as the 
abc gene and is therefore regulated in trans. 
linkage analysis of gene expression profiles in the offspring of a yeast cross and were 
able to define co-ordinated patterns of gene expression. They measured expression of 
all 6125 genes and detected over 1500 as differentially expressed between the parental 
yeast strains. Expression was also measured in 40 haploid offspring and 570 eQTL 
were identified of which 308 were in the genes differentially expressed between the 
parents. They concluded that differential gene expression is highly heritable and that 
there is a high rate of cis-acting alleles and a small number of trans-regulating factors 
with widespread effects. Eight trans-acting loci were found to act on five or more 
regions, each of which controlled expression of up to 100 genes of related function. 
In a follow up paper Yvert et al (Yvert et al. 2003) used this data in a cluster analysis 
and detemuned that one third of all genes could be clustered. Each cluster when 
annotated was found to contain genes involved in similar processes. In addition, 
linkage of these clusters to the region of the genome controlling the expression of the 
genes in the cluster was carried out to identify trans-acting factors. 
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Schadt and colleagues (Schadt et al. 2003) were the first to utilise this approach in a 
mammalian system, using a mouse F2 population. Frorn a total of approximately 
twenty-three thousand genes, 7,861 were deten-nined to be differentially expressed in 
the parents or 10% of the F2 animals. Also without filtering for differential 
expression 4,339 eQTL were detected in 3,701 genes. Again genes determined to be 
controlled in cis resulted in higher LOD scores than those eQTL which were fi-ans- 
regulated. They also discovered "eQTL hotspots", regions of the genome containing 
more eQTL than would be expected by chance, which could be indicative of possible 
regulatory elements which control expresslon of many genes. These regulatory 
elements could explain the correlation of expression patterns of genes on a particular 
pathway. Finally using cluster analysis this study identified both a gene expression 
pattern strongly associated with obesity and two obesity subtypes within the group, 
that were under the control of distinct loci. This is similar to the cancer classification 
decribed in Section 1.7.1. 
Overall these studies demonstrate the power of this approach iii that parental 
differences in gene expression were shown to be highly heritable and that known 
pathways can be detected. 
1.8 Comparative Genomics 
Comparative genomics or comparative inapping is a powerful approach to identify 
systematically genes and the important regulatory elements in 
human by looking at 
evolutionary conservation. It exploits the similarities and 
differences between the 
sequences of genomes of different organisms to 
determine which nucleotides have 
remained the same over long periods of time, that is, since 
the animals split in 
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evolutionary history. This provides important insights into gene structure and 
function and can thereby be used to develop strategies to combat human disease based 
on the analysis of the genomes of model organisms. 
1.9 Aims of this work 
The present study aims to use transcriptional profiling in a segregating population to 
integrate the substantial body of genetic and phenotypic data available for the 
BXH/HXB RI strains by generating and mapping gene expression profiles across the 
30 strains (and SHR and BN/Lx parentals) using DNA microarray technology. 
Following generation of gene expression data for the RI strains, expression profiles 
are mapped as a quantitative phenotypes. The clustering and map location data that 
will be derived will provide a new description of the metabolic pathways that mediate 
cardiovascular and metabolic traits represented within these RI strains and will 
suggest new regulatory control points and interactions between these pathways. 
The specific aims presented in this thesis are to: 
1. generate microarray data for the BXH/HXB recombinant inbred strains and 
SHR and BN/Lx parental strains. 
2. use linkage analysis of the microaiTay data set to identify differentially 
expressed genes that are controlled in cis and in trans. 
3. prioritise genes as candidates for sequencing in the promoter region to identify 
variants which may underlie the differential expression and thus 
biological 
phenotype in cis-regulated eQTL. 
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4. carry out comparative mapping of cis eQTL to identify potential candidate 
genes for human cardiovascular and metabolic phenotypes. 
Chapter 3 describes the generation of the microarray data sets and the linkage 
analysis carried out. It also discusses some of the quality control and preliminary 
analyses performed on the data to assess the optimum methods. 
Chapter 4 examines a subset of the cis-acting eQTL to look for polymorphisms in the 
putative promoters of these genes. These polymorphisms may cause the differential 
expression detected in these strains and underlie the phenotypic variation seen. 
Chapter 5 describes a comparative mapping study carried out using human QTL for 
metabolic and cardiovascular phenotypes to identify rat cis-acting eQTL and their 
human orthologs as potential candidate genes. 
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Chapter 2: Materials and methods 
2.1 Stock solutions 
2.1.1 Solutions for DNA and RNA analysis 
10 x MOPS 41.8g MOPS, 16.6ml DEPC-treated 3M sodium acetate (pH 
5.2), 20ml DEPC-treated 0.5M EDTA in 800ml of ddH-, O. 
Adjust pH to 7.0 with 5M NaOH. Adjust volume to 11 with 
ddH20- Filter-sterilise and store in the dark. 
10 x TBE 108g Tris base, 55g boric acid, 40ml 0.5M EDTA (pH 8) In 11 
of ddH-, O. Stir until the solutes have dissolved. 
DEPC water Iml of diethyl pyrocarbonate (DEPQ per 500m] of water. 
Shake and leave overnight before autoclaving. 
EDTA 186g Na2EDTA in 800ml of water. Adjust pH to 8.0 with 5M 
NaOH. Adjust volume to II with ddH-, O. 
Loading buffer 0.25% w/v bromophenol blue, 0.25% w/v xylene cyanol, 30% 
w/v glycerol in water. 
Lysis buffer I 00raM Tns-HCI (pH 8.5), 5mM EDTA, 0.2% SDS, 200mM 
NaCl in water. 
Proteinase K 20mg/ml in H, O, stored at -20'C. 
RNA loading buffer 200ýtl 2.5% bromopbenol blue, 200pl 2.5% xylene cyanol, 
400ýtl 0.5M EDTA in 9.2ml cleionised fon-namide. Aliquot and 
store at -20'C. 
RNA premix 2.5ml 10 x MOPS, 4.4ml 37% formaldehyde, 12.5ml 
deionlsed 
formamide. Store at -20'C in single-use aliquots. 
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TE buffers Various combinations of Tris-HCI and EDTA 
TI()Eo., (pH 7.5); 1 OmM Tris-HCI, 0.1 mM EDTA (pH 7.5). 
2.2 Preparation of DNA 
2.2.1 Extraction of DNA from rat tissue 
Typically 
The DNA extraction protocol was modified from Laird et al. (Laird et al. 1991). 
Genomic DNA was extracted from rat liver tissue. AfterC02 narcosis, animals were 
sacrificed by cervical dislocation. Tissues were removed quickly, placed in bijous 
and immediately placed into liquid nitrogen. For long-term storage, tissues were kept 
at -70'C. 
A small piece of tissue was removed from -70'C storage and added to 750pl of lysis 
buffer plus proteinase K at I OOpg/ml in an eppendorf. Lysis was carried out 
overnight, at 55'C in a gyratory water bath. Following lysis, the samples were 
vortexed then centrifuged in a bench-top microfuge (Eppendorf, Cambridge, UK) at 
10,000 rpm for 10 minutes. The supernatant was placed in a fresh tube, 750pl of 
isopropanol was added and the sample mixed until precipitation was complete. The 
DNA was removed using a sterile plastic loop and resuspended in 50OVtl of TE. 
DNA yield and purity was determined by absorption at 260nm and 280nm UV using 
the Gene Quant spectrophotometer (Amersham Pharmacia Biotech UK Ltd, Little 
Chalfont, UK). An OD unit of 1.0 indicated a concentration of 50pg/ml of double 
stranded DNA. The 260nn-1/280nm ratio was expected to fall between 1.7 and 
2.0. 
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2.3 Preparation of RNA and cDNA 
2.3.1 Extraction of RNA from rat tissue to select and optimise procedures 
RNA was extracted from rat perltoneal fat and whole kidney tissue. After C02 
narcosis, animals were sacrificed by cervical dislocation. Tissues were removed 
quickly, to avoid RNA degradati III into 'on, placed in bijous and placed - 
liquid nitrogen. For long-term storage, tissues were kept at -70'C. 
Two methods were tested for RNA extractions: - 
1) RNA was extracted from tissue using the RNAzoll"'I B reagent (BioGenesis, 
Poole, UK). Frozen tissue was hornogenised in 2ml of RNAzol I"B per I 00mg of 
tissue, 0.1 volumes of chloroform was added and the samples shaken vigorously. 
After incubation on ice for 5 minutes, the suspension was centrifuged at 12,000g for 
15 minutes. The aqueous layer was transferred to a fresh tube, I volume of 
isopropanol was added and the sample incubated at 4'C for 15 minutes. The sample 
was centrifuged at 12,000g for 15 minutes and the supernatant removed. The RNA 
pellet was washed once with 75% ethanol and resuspended in DEPC-treated I mM 
EDTA, pH 7. The RNA sample was stored at -70'C in single-use aliquots. 
2) RNA was extracted from tissue using the Trizo ITM reagent (Invitrogen, Paisley, 
UK). Frozen tissue was homogenised in 51nl of 
TrIZOITM per I 00mg of tissue and 
incubated at room temperature for 5mins. Next, 0.6mls per 100mg of tissue of 
chloroform was added and the samples shaken vigorously. After incubation at room 
temperature for 2-3 minutes, the suspension was centrifuged at 12,000g 
for 15 
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minutes. The aqueous layer was transferred to a fresh tube, I volume of isopropanol 
was added and the sample incubated at room temperature for 10 minutes. The sample 
was centrifuged at 12,000g for 10 minutes and the supernatant removed. The RNA 
pellet was washed once with 4mls of 75% ethanol and resuspended in DNase/RNase 
free water (Sigma-Aldrich, Irvine, UK). The RNA sample was stored at -70'C in 
single-use aliquots. 
RNA yield was deten-nined through absorption at 260ni-n UV and v1sualised initially 
on a 1% agarose gel with formaldehyde and ultimately using the Agilent bioanalyser. 
An appropriate dilution of the RNA was made and the OD at 260nm and 280nm UV 
was read using the Gene Quant spectrophotorneter (Amersham Pharmacia Biotech 
UK Ltd, Little Chalfont, UK). An OD unit of 1.0 indicated a concentration of 
40pg/ml of RNA. The 260niTi/280nm ratio was used to assess the purity of the RNA 
sample and was expected to be in the range of 1.7 to 2.0. 
2.3.2 First strand cDNA synthesis 
Prior to first strand cDNA synthesis, total RNA was treated with Arnplification Grade 
DNasel (Invitrogen, Paisley, UK) which was inactivated by addition of a final 
concentration of 2.5mM EDTA and incubation at 65'C for 10 minutes. The DNase 
digested RNA was reversed transcribed into cDNA with the I st Strand Synthesis Kit 
according to manufacturers instructions (Roche, Lewes, UK). Synthesis was carried 
out in a 20pl reaction volume with Ix reaction buffer, MgCl-, 
(5mM), dNTPs (Im, M), 
random primer (3.2ýtg), RNase inhibitor (50U) and 
AMV reverse transcriptase 
(>20U) with 8.2pl of DNase digested RNA. The sample was 
incubated at 25'C for 10 
minutes, followed by 42'C for 60 minutes and 
99'C for 5 minutes. The cDNA was 
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purified through a G50 Spin Column (Amersham Pharmacia Biotech UK Ltd, Little 
Chalfont, UK) and stored at -20'C. 
2.4 Amplification of DNA (PCR) 
2.4.1 Standard protocol for PCR 
PCR primers were designed both by hand and using Primer 3 
(http: //frodo. wi. mit. edu/cgi-bin/primer3/prime_3www. cgi). Primer pairs were 
checked to ensure non-complementary 3' ends and designed to ensure that the primers 
had a similar melting temperature (Tm). Tm was calculated as: 
2(A + T) + 4(G 
Oligonucleotide primers were synthesised by SigmaGenosys Biotechnoloýy 
(Cambridge, UK). When Primei-3 was used the rodent and simple mispriming library 
was selected and the default settings of primer length 20 with Tm of 60'C Nvere used 
and they were also checked by eye and using the above fon-nula. 
PCR reactions were performed In I Opl volumes and contained a final concentration of 
Ix reaction buffer, 0.2mM dNTPs, 0.66pM of each oligonucleotide primer and 0.5U 
of Taq polymerase (Bioline, London, UK). Optimised concentrations of M9Cl-, were 
used with the final concentration in the range of 1.0 - 2. OmM. Genomic DNA was 
used at a final concentration of 5ng/[tl. Stock solutions were stored at -20'C. PCR 
reactions containing water instead of DNA as a 'water blank', were also performed to 
act as negative controls. 
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PCR was camed out in 96-well plates or individual 0.2ml tubes (ABGene, Epsom, 
UK) without an oil overlay using a Tetrad thermal cycler (MJ Research, Rayne, UK). 
96-well plates were sealed with heat-sealing foil and a Thermo-Sealer (ABGene, 
Epsom, UK). Standard amplification conditions were 94'C for 3 minutes, followed 
by 30-40 cycles consisting of denaturation at 94'C for 30 seconds, an optimised 
annealing temperature for 45 seconds, extension at 72'C for I minute and final 
extension at 72'C for 8 minutes. If Amplitaq Gold (Applied Biosysterns, Warrington, 
UK) was used, the initial denaturation step was increased to 12 minutes. 
Each primer pair was optimised for MgCl, concentration in the range of 1-2.5inM. 
Most primers were used at 1.5mM MgC]-,. Each primer was also optimised for 
annealing temperature in the range of 50'C to 65'C, according to the Tm of the 
primers. 
2.5 Gel electrophoresis 
2.5.1 Agarose gel electrophoresis 
Agarose gel electrophoresis was carried out using horizontal submarine agarose gels. 
For agarose mini-gels, 10cm wide 1-nini Sub TN I cells were used (Bio-Rad, Hemel 
Hempstead, UK) with Ix TBE used as gel buffer and running buffer. Gels were 
made by dissolving agarose powder (Invitrogen, Paisley, UK) in gel buffer and 
boiling in a microwave. Agarose was cooled to 60'C before pouring. Agarose 
concentrations ranged between I% and 4%. For agarose gels of concentration greater 
than 3%, standard agarose and NuSieve agarose (Flowgen, Ashby 
de la Zouch, UK) 
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were combined in a ratio of 1: 3. Ethidium bromide was added to the gel and running 
buffer using 2pl of 5mg/ml stock per I 00ml of gel or running buffer. DNA samples 
were loaded with 1/3 volume of loading buffer and electrophoresis carried out at 120 
volts for 30 - 45 minutes. ýx174IHaelll (AB Gene, Epsom, UK) and XlHindlll 
fragments (Invitrogen, Paisley, UK) were used as DNA size markers. 
DNA was visualised using a UV transilluminator (Camlab Ltd, Cambridge, UK) and 
photographed using polaroid film taken on a Polaroid MP4 land camera (Kodak, 
Hemel Hempstead, UK) with a red filter. 
2.5.2 Denaturing gel electrophoresis 
Formaldehyde gel electrophoresis was carried out to separate total RNA. Separate 
chemicals, designated for RNA work, were used for all these experiments. Ix MOPS 
was used as running buffer for 15cm wide Sub'r"' cell (Bio-Rad. Hemel Hempstead, 
UK) formaldehyde gels. Fon-naldehyde gels were made by dissolving agarose powder 
(Invitrogen, Paisley, UK) in DEPC-treated water and boiling in a microwave. 
Agarose was cooled to 60'C and 10 x MOPS and formaldehyde were added. The gel 
was poured and allowed to set for 40 minutes. Five micrograms of RNA was 
combined with RNA premix, RNA loading buffer and ethidjurn bromide (0.5pg/pi). 
Samples were incubated at 55'C for 15 minutes and quenched on ice. Electrophoresis 
was camed out at 70 volts for 3 hours. 0.24-9.5kb RNA ladder (Invitrogen, Paisley, 
UK) was used as RNA size standard. 
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Following electrophoresis, RNA was visualised using a UV transilluminator (Camlab 
Ltd, Cambridge, UK) and photographed using polarold film taken on a Polaroid MP4 
land camera (Kodak, Hemel Hempstead, UK) with a red filter. 
2.6 Agilent Bioanalyser 
To assess RNA quality, I [d of RNA (25-500ng) from each sample was tested using 
the Agilent Bioanalyser RNA 6000 Nano assay. Each chip can assess 12 samples 
simultaneously. Before use, the Bioanalyser electrodes were decontaminated by 
applying one electrode cleaner with 350ýtl of RNAZap (Ambion, Huntington, UK) to 
the electrodes for one minute followed by one electrode cleaner containing 350pi of 
water for 10 seconds. The electrodes were then allowed to dry. Filtered gel matrix 
was prepared by pipetting 550pl of RNA matrix into a spin filter and centrifuging at 
1500g for 10 minutes. This was aliquoted into 65pI aliquots for use. Immediately 
prior to running the Bioanalyser assay I pl of vortexed RNA dye concentrate was 
added to a 65ýil aliquot of filtered gel matrix and centrifuged at 13,000g for 10 
minutes. 91il of this gel dye i-nix was used to prepare the RNA 6000 nanochip in the 
chip priming station. Once the chip was primed another 9p] was pipetted into eacli 
well of the chip marked with a G. 5VI of RNA 6000 Nano Marker was added to the 
remaining 13 wells of the chip. I [tl of each sample and I pl of RNA 6000 Ladder 
were denatured at 70'C for 2 minutes and placed on ice before being added to the 
wells on the chip. The chip was then vortexed for I minute and run on the Eukarvofic 
iotal RNA Nano assay. 
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2.7 Preparation of RNA, cDNA and cRNA for Affymetrix 
GeneChipTM studies 
2.7.1 Extraction and purification of RNA from rat fat tissue 
One peritoneal fat pad from each animal in the study was added to 3ml TriZOITM fo r 
homogenisation. RNA extraction was carried out as detailed in Section 2.3.1 
(Method 2). 
RNA samples were purified using the RNeasy Mini Kit (Qiagen, Crawley, UK). 
RNA was extracted and purified from 4 animals of each rat RI strain and 5 from each 
parental strain. RNA samples were concentrated to 2ýtg/pl by ethanol precipitation as 
follows. First the sample was added to an 1.5ml eppendorf tube containing 3x volume 
of 100% ethanol and I/ 10 volume of sodium acetate (pH 4.6). Tubes were vortexed 
and allowed to stand at room temperature for 15 minutes. The samples were then 
centrifuged in a bench-top microfuge (Eppendorf, Cambridge, UK) at maximum 
speed for 20 minutes. The supernatant was removed, and the pellet washed with 70% 
ethanol. Following vortexing, centrifugation and removal of the supernatant, the 
pellet was air-dried at room temperature. Pellets were resuspended in the appropriate 
volume of DNase/RNase free water to ensure the RNACODcentratjon was 2pg/pl. 
2.7.2 Double stranded cDNA syntbesis and purification 
Ten micrograms of total RNA was incubated at 70'C for 10 minutes with I OOpmol 
T7-(T)24primer and Poly A+ controls. After incubation and quenching on ice, first 
strand synthesis was carried out in a 20pl reaction volume with Ix First strand 
buffer, 
0.1 M DTT, I OmM dNTPs and 40OU Superscript 11 reverse transcriptase (Invitrogen, 
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Groningen, The Netherlands). Samples were incubated at 42'C for I hour and 
quenched on ice before proceeding to second strand synthesis. 
Second strand cDNA synthesis was performed on each sample with Ix Second strand 
buffer, I OmM dNTPs, I OU DNA figase, 40U DNA Polymerase I and 2U RNase H 
(Invitrogen, Groningen, The Netherlands) to a final volume of 150pl. Samples were 
incubated at 16'C for 2 hours. 
The double stranded cDNA was purified using GeneChip 9 Sample Cleanup module 
(Affymetrix, Santa Clara) according to the manufacturer's instructions. 
2.7.3 cRNA syntbesis and purification 
cRNA was generated to allow the incorporation of biotin-labelled nucleotides for 
detection of microarray hybridisation. Jn vitro transcription was performed on double 
stranded cDNA preparations using the Bioarray High Yield RNA Transcript Labelling 
Kit (Enzo Diagnostics Inc., New York, USA) which contains biotin-labelled 
nucleotides. Samples were incubated at 37'C for 5 hours, with gentle agitation at 
hourly intervals. 
cRNA samples were purified using the, GeneChipi) Sample Cleanup module 
accord]Dg to the manufacturer's instructions. 
cRNA yield and quality was deten-nined through absorption at 260nm UV and using 
the AgIlent Bloanalyser as described in Section 2.6. An approprIate d1lutlon of the 
cRNA was made and the OD at 260nm and 280nm UV was read USiDg the 
Gene 
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Quant spectrophotometer (Amersham Pharmacia Biotech UK Ltd, Little Chalfont, 
UK). An OD unit of 1.0 indicated a concentration of 40pg/ml of cRNA. cRNA 
yields were expected to be in the range of 40 to II Opg. The 260nni/280nm ratio was 
expected to be in the range of 1.8 to 2.1. 
2.7.4 Hybridisation of cRNA to Affymetrix GeneChips 
Biotin-labelled cRNA samples were given to the Imperial College Microarray Centre 
for fragmentation and hybridisation to Test chips and GeneChips TM according to the 
protocol provided by Affymetrix (High Wycombe, UK). After hybridisation of the 
biotinylated cRNA, streptavidin-phycoerythrin (SAPE) and a secondary biotinylated 
goat anti-streptavidin antibody is added to the hybridisation mix. Briefly, the SAPE 
binds to the biotinylated cRNA and is subsequently bound by the goat anti- 
streptavidin antibody which is also biotinylated. The addition of a second dose of 
SAPE amplifies the hybridisation signal. In these studies, all arrays were analysed 
after antibody amplification. IOVtg of cRNA was hybridised to a Test chip to assess 
protocols (e. g. background signal, signal to noise ratio, percentage of present calls) 
before the RI strain and parental samples were applied to the RAE230A GeneChipTNI 
JpTM. 'pSTM 15pg cRNA was hybridised to each GeneChi Initial analysis of the GeneChi 
was carried out using Microarray Analysis Suite 5.0 (Affymetrix, Santa Clara, 
CA, 
USA). This software gives present, marginal or absent calls for each gene or EST and 
generates values for the average difference in signal between perfect match and 
mismatch probes. 
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2.7.5 Expression data from Rl strain kidneys 
A second data set was generated in the FJ strains by Norbert HObners' group In the 
Max-Delbriick Centre, Berlin using the kidney tissue frorn the same animals used in 
the adipose tissue experiments in London and also hybridised to Affymetrix R230A 
GeneChips. This student acknowledges permission to include this data set in this 
thesis as it provides a comparison for the fat data set and a more complete data set 
overall since both tissues are involved in the metabolic syndrome. 
2.8 Sequencing of PCR products 
Template was prepared from a 50p] PCR reaction. PCR was performed as per the 
standard PCR protocol (Section 2.4.1), and all volurnes were scaled up in proportion. 
5pl of the PCR product was resolved on an agarose gel to check that a single, intense 
band had been amplified. The. remaining 45ýtl was purified through a Centricon 100 
colurrin (Millipore, Watford, UK) according to manufacturer's instructions. If a single 
band could not be obtained, the bands were excised from the gel and the DNA was 
purified using the QiaQuick Gel Purification System (Qlagen Ltd, Crawley, UK). 
Template reactions were prepared containing 30-90ng of purified PCR product and 
3.2pmol of primer, with water added to a final volume of 10pl. Template reactions 
were given to the local sequencing service for cycle sequencing, purification and 
electrophoresis according to the protocols given below. 
Cycle sequencing was performed on a Perkin Elmer 9700 Thermal 
Cycler using the 
BigDye v3.1 Sequencing Kit (Applied Biosystems, Warrington, 
UK). Five 
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microlitres of template reaction was added to 0.9[11 of BigDye, 2p] of water and 2PI 
5X buffer. Reactions were cycled with an initial denaturation step at 9611C for I 
minute, followed by 35 cycles consisting of 96'C for 10 seconds, 52'C for 15 seconds 
and 60'C for 4 minutes. 
Cycle sequencing products were purified using EDTA-EtOH chemistry clean up. Five 
microlitres of 125m-M EDTA and 30pl of 100% Ethanol is added to 10pl of 
sequencing reaction and incubated at room temperature for 15mins before 
centrifugation at 3,000g for 30mins. The pellets are washed once with 100% ethanol 
and then twice with 70% ethanol. The DNA is resuspended in 10-12p] of HiDj 
Formamide. Sequencing was performed on an ABI 3730 DNA Analyser (Applied 
Biosystems, Warrington, UK) for 4.5 hours. DNA sequences were analysed using 
both Sequence Navigator and Sequencber software (Applied Biosystems, Warrington, 
UK). 
2.9 Linkage Analysis and definition of eQTL 
2.9.1 Mapping of eQTL 
2.9.1.1 Using Map Manager QTX 
Expression QTL were mapped initially probe set by probe set using the Map Manager 
QTX program (Manly et a]. 2001). This program generates likelihood ratio statistics 
for one quantitative trait (QT) to all the markers in the genorne. Therefore each probe 
set (which is in essence a QT) needs to be added individually. 
Genes were prioritised 
based on the fact that they were differentially expressed in the parental strains since it 
was not practical to input all 15,000 probe set values 
from the microarray manually. 
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At the time no outlier detection could be carried out as not enough replicates were 
available. Mean expression values for each RI strain were derived and entered into 
the Map Manager program to generate a list of significantly linked markers for that 
probe set. 
2.9.1.2 Mapping eQTL across the whole genome using QTL Reaper 
Mean expression values from the four replicates for each RI strain and in the fat and 
kidney tissue were derived after application of the Nalimov outlier test at P< 10-3 
This test was carried out by Dr Enrico Petretto of the Physiological Genomics and 
Medicine group. Genome-wide linkage analysis for each of the 15,923 expression 
traits and the 1,011 genetic markers was carried out using the QTL Reaper program 
(C 2002 Kenneth F. Manly) which generates a likelihood ratio statistic (LRS) as a 
measure of the significance of a possible eQTL. QTL Reaper establishes genome- 
wide significance by permutation test, estimating an empirical genome-wide 
probability for observing a given LRS score by chance (Churchill and Doerge 1994). 
For each probe set pennutations are carried out until a LRS greater than that for the 
real data is observed, or 1,000,000 permutations have been done, conditional on at 
least 1,000 permutations being performed. The permutation procedures for the QTL 
Reaper program correct for individual expression pbenotypes for multiple testing 
across genetic markers to give a genome-wide corrected P-value, but not for multiple 
testing across the 15,923 expression measurements. The number of falsely discovered 
linkages at a given genome-wide significance level was estimated by Dr Enrico 
Petretto. The q-value (Storey 2002), which is defined as the minimum positive FDR 
for a fixed significance threshold was calculated. 
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2.9.3 Definition of cis- and trans-acting eQTL 
Following the QTL Reaper analysis the eQTL defined were classified as being 
regulated in cis, that is by the gene itself or in trans, by another gene. cis-acting 
eQTL, are defined in this thesis as when the most significantly linked marker maps 
IOMb up or down stream of the physical location of the probe set. eQTL where the 
marker was more distant than I OMb or on another chromosome were defined as being 
regulated in trans. The analysis to define all eQTL as either cis or trans was 
automated using an algorithm devised by Michael Muller in the group following 
discussion of the method and decision on the size of the cis window with this student 
and Drs Caroline Wallace and Enrico Petretto. 
2.10 In sifico analysis 
Probe set details such as sequence and mapping information were obtained from the 
Aftymetrix NetAffx analysis centre (http: //www. netaffx. com). Physical locations of 
probe sets were obtained from Affymetrix, or by mapping to the genome using 
BLAST both at Ensembl (http: //www. ensembi. org/Rattus_iiorvegicus/blastview) and 
NCBI (bttp: //www. ncbi. nlm. nih. gov/BLAST/). Finally, during the time this work 
was being carried out both the Ensembl and UCSC (http: //genome. ucsc. edu/) genome 
browsers mapped all Affymetrix probe sets to the genome assemblies and these were 
used to locate probe sets as this data became available. 
Previously mapped SHR physiological QTL were identified using the Rat Genorne 
Database (http: //rgd. mcw. edu/). These were then checked against the reference 
sequences to ensure reported P-values and peaks of linkage were correct. 
In addition, 
a literature search was carried out using 
Pubmed 
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(bttp: //www. ncbi. nlm. nib. gov/entrez/) and Google (bttp: //www. google. comý to 
ensure all SHR pQTL were recorded. 
Human QTL from genome wide scans for type 2 diabetes, insulin resistance, 
dyslipidernia, hypertension and cardiovascular phenotypes were collated. RGD was 
again used as a basis for this and the information from there was checked against the 
orginal references and a literature search, again using Pubmed, was carried out to 
identifý other QTL not already included in RGD. 
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2.11 Description of the generation and analysis of data sets used in 
this thesis 
Figure 2.1 Flowchart describing the preliminary data sets 
The preliminary data sets were used to generate Figure 3.6 and Figure 3.9. There 
were six gene expression profiles from the parental strains normalised by both 
MAS5.0 and RMA algorithms. These data sets were used to compare the 
normalisation methods. RMA was selected and used to select genes that were 
differentially expressed in the parental strains. These 47 genes were then tested for 
linkage in the available 97 expression profiles RI strains using Map Manager QTX 
The most significantly linked marker for each probe set was selected and these are 
shown in Figure 3.6 and Figure 3.9. Twenty of these were selected for sequencing in 
the target region. 
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Figure 2.2 Flowchart describing the final data set 
The final data set was analysed in Chapter 4. There were 130 gene expression 
profiles from fat tissue and 129 from kidney tissue, each of these includes 10 from the 
parental strains and the rest are from the RI strains. Linkage analysis was carried out 
in the RI strain data using QTL Reaper. Redundant markers that had the same genetic 
locations and the same SDP were removed. There were 2118 eQTL in fat and 2490 in 
kidney, the location of the marker relative to its linked probe set were calculated and 
those in cis and with pý_104 were selected for study. This left 97 in fat and 129 in 
kidney, this data was then reduced by selecting genes with a two-fold differential 
expression in the parental strains. Twenty-two eQTL were discarded because they did 
not have sufficient mapping information. The final data set sequenced in Chapter 4 
was comprised of the 15 eQTL that represented 14 genes and an additional 4 genes 
that had been studied previously and matched either the fold change or P-value 
criteria. 
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Chapter 3: Microarray data generation, quality control, 
normalisation, validation and linkage analysis 
3.1 Introduction 
The overall aim of the work in this chapter was to generate, validate and normalise 
microarray data from 30 RI strain and the BN and SHR parentals and to carry out 
linkage analysis of gene expression profiles to locallse and ultimately identify genes 
which may play a causal role in SHR metabolic phenotypes. 
The study design here was to extract fat and kidney RNA from 4 animals per RI strain 
and 5 animals in the BN and SHR parental strains and to hybridise them to 
Affymetrix GeneChips. This is a large data set and was generated in 2 centres: the 
kidney data by Dr Norbert Hubner's group at the Max-Delbruck centre (MDC) in 
Berlin. This student generated the data from 66 of the 130 tissue samples with the 
remainder being generated by Dr Caroline Wallace of the Physiological Genomics 
and Medicine group (Appendix 1). 
Gene expression studies 
As discussed in the Introduction section 1.7 the recent development of microarray 
technology has allowed the study of expresslon of thousands of genes and thus the 
entire genome simultaneously. 
Rat Expression Analysis 230 (RAE 230) A Genechip'* Affymetrix oligonucleotide 
microarrays were used to generate expression values in the 
SHR and BN parents and 
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all 30 FJ strains. This is one of two arrays in the R-AE 230 set and represents 
approximately 16,000 genes in the rat genome and contains genes which were 
represented on the previous Rat U34A GeneChip. A probe set is designed for each 
gene containing II probe pairs which are used to determine if the gene is expressed in 
the RNA sample. There are two types of probe in a probe pair: one perfect match 
(PM) and one mismatch (MM) both of 25 nucleotides M length (Lipshutz et a]. 1999). 
The perfect match probe is exactly complementary to the RNA target sequence of the 
transcript while the mismatch probe differs by a single base in the central (13 1) 
position and is used to detect non-specific hybridisation and therefore deten-nine 
background measurements. The probe pairs are distributed across the chip and the 
infounation from each probe pair is combined (summarised) to derive an expression 
measure for the geiie. 
3.1.2 Data extraction and normalisation methods 
There are several methods to summarise probe intensities from each probe in a probe 
set. Two methods were compared in the work presented here; the Affymetrix 
Microarray Analysis Suite 5.0 (MAS5.0) (Affymetrix, Santa Clara, CA, USA) and the 
Robust Multi-array Analysis (RMA) method developed by Irizarry (Irizarry et aL 
2003). Both methods use the "* cel" files to extract expression values for each gene 
in the sample, these files contain the captured image of the scanned array and the raw 
intensities for probe sets. The first method used: the MAS5.0 software gives present 
(P), marginal (M) or absent (A) calls for each gene or EST and generates values 
for 
the average difference in signal between perfect match and mismatch probes. 
The 
average difference is calculated from the combined background adjusted 
PM and MM 
values of the probe set. The data was extracted using the 
MAS5.0 software 
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(Affymetrix 2002) and then normalised using Microsoft Excel by scaling the raw 
average difference to the median of the medians of all the GeneChips in the analysis. 
This will be referred to as median scaling. 
The second method RMA, uses raw probe set data ("* cel" files) and simultaneously 
nonnalises the data using a quantile normalisation. This eliminates systematic 
differences between GeneChips, without significantly altering the relative intensity of 
probes within a GeneChip. The data is transforined to the 1092 scale and a mediaii- 
polish procedure is used to combine multiple probes into a single measure of 
expression for each gene on each array. The quantile normalisation aims to make the 
distribution of probe intensities for each array in the data set equal. 
3.1.3 Quality control indices 
During the derivation of this data set the quality of the RNA, cRNA and hybridisation 
were tested. Since the data was being generated by two people it was important to 
ensure the data was consistent and therefore could be analysed and compared 
together. Similar quality control was applied to the kidney data set at the MDC in 
Berlin. The Agilent Bioanalyser can be used to assess the quality of both the 
extracted RNA and the cRNA synthesized before the sample is hybridised to the 
microarray. The yield of cRNA was also deten-mned and only In vitro transcription 
reactions achieving 35pg of cRNA or more were hybridised. 
Affymetrix MAS 5.0 
software was used to extract the data from the microarrays to assess 
the quality of 
each hybridisation reaction based on the Raw Q and percentage 
P value. Raw Q is a 
measure of quality control which considers the pixel 
to pixel variation of probe cells 
on a GeneChip array. A maximum threshold 
Raw Q value of 4 was used in this study 
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following preliminary experiments using Affymetrix Test arrays and fat tissue 
samples from peritonea] fat pads of rats of similar age to that used in this experiment. 
This threshold was based on a guide from Affymetrix and also our observation that 
generally cRNA from fat samples resulted in a slightly higher Q than samples from 
other tissues. Any sample which produced a Raw Q value of 4 or over was excluded 
from the study and the cRNA synthesis repeated. Percentage P is the percentage of 
genes on the array which are called present by the MAS5.0 software that is genes that 
are detected in the bybridised RNA sample. 
3.2 Results 
3.2.1 Generation and quality control of microarray data sets 
Two complete data sets were generated with a total of 130 and 129 microal-rays in fat 
and kidney respectively. This student generated 66 of the 130 microarrays from the 
fat data set which was combined and normalised with the other 64 to facilitate 
effective analysis of the data and comparison with the kidney data set. This student 
acknowledges Dr Caroline Wallace for permission to include this data since this 
allows statistical analysis and interpretation of the whole data set. A table of samples 
prepared by the student and Dr Wallace is given in Appendix I 
Prior to carrying out RNA extractions, cRNA synthesis and hybridisations on the 
tissues from the RI strains a number of test samples were used to determine which 
protocols were optimal. These samples were peritoneal fat pads 
from age matched 
rats to allow determination of which RNA extraction protocol yielded more 
RNA. 
RNABee and Trizol protocols were compared and with 
both fat and kidney tissue 
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Trizol consistently gave a higher yield of RNA with better A260/280 ratios. Table 
3.1 shows representative samples frorn this analysis. Normally a formaldehyde gel is 
used to assess both RNA and cRNA quality, however this uses 2.5pg of RNA while 
the Agilent Bioanalyser only uses between 25-500ng of the RNA sample. The fat 
pads used in this study were from 6 week old animals and varied in size depending on 
which strains they originated from. Consequently they yielded small arnounts of 
RNA and often just enough to carry out cRNA synthes's (IOVtg), therefore the 
technique using the lowest arriount of RNA used to determine quality was preferable. 
Thus a comparison was carried out between the bioanalyser and a fornialdehyde gel to 
determine if they gave the saine results. The sarne six test RNA and six test cRNA 
samples were run on both a formaldehyde gel and a bioanlyser trace. Figure 3.1 
shows gel images from both methods, the bioanalyser generates an artificial gel irnage 
following the trace. The 6 lanes on left of each gel in Figure 3.1 contain the same 
total RNA samples with the expected bands corresponding to 28S and I SS ribosonial 
RNA detected. The last 6 lanes on each image show cRNA sample traces frorn the 
same samples. cRNA should result in a smear on electrophoresis as it represents the 
heterogeneous population of rnPNA present in a tissue. The lack of any distinct 
bands is an indicator of quality. Since the methods gave corresponding results for 
quality and the Bioanalyser requires significantly less sample it was decided to use it 
to assess the RNA and cRNA quality. 
A260 A280 Ratio yield (pg) 
Fat RNA Bee 0.25 . 128 
1.98 500 
Kidney RNA Bee 0.349 0.11 1.61 698 
Fat Trizol 0.34 0.164 2.07 680, 
Kidney Trizol 
A- 
0.539 0.169 1.582. 10781 
Table 3.1 Comparison of RNA yield using RNA Bee and Trizol 
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Hybridisations using test 3 arrays were also carried out on these preliminary fat tissue 
samples to ensure the cRNA synthesized would be suitable for RAE230A GeneChIps 
and to deten-nine expected Raw Q and percentage P values in fat tissue samples. Ten 
samples were checked on test arrays and this showed that fat tissue samples give a 
higher Raw Q than the recommended value of 3 and therefore when the study samples 
were hybridised a higher threshold of 4 was permitted in fat tissue. 
Following these protocol assessments RNA was extracted from peritoneal fat tissue 
from 4 animals per RI strain and 5 animals for each parental strain (Methods 2.3.1) 
and was concentrated to 2[tg/pl by ethanol precipitation. cRNA was generated 
(Methods 2.7) and those samples passing quality control were hybridised to the 
microarray. Those samples which did not pass the quality control were not hybridised 
and more cRNA generated either from the remaining RNA or from new RNA 
extracted from the other fat pad of the same animal. 
The yield and purity of the RNA and cRNA samples were determined using the 
A260nin/280nm ratio. Only samples which had a 260nm/280nm ratio of between 1.8 
and 2.1 were hybridised to the GeneChips. The quality of the RNA and cRNA was 
also assessed using the Agilent Bioanalyser and example traces are shown in Figure 
3.2. Figure 3.2A shows traces from two total RNA samples, the trace in blue is 
indicative of good quality RNA with two peaks of approximately equal heights 
corresponding to 18S and 28S ribosomal RNA which should be present in equal 
quantities in a good total RNA sample. The trace in green which has no distinct peaks 
and a definite leftward shift is typical of a degraded RNA sample. All RNA samples 
were assessed and only those showing good quality traces were used to make cRNA. 
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In the case of samples which failed quality the RNA was re-extracted from the other 
fat pad or from the fat pads of a new animal from the same strain. Following cRNA 
synthesis and clean-up the samples were again run on the Bioanalyser and 
representative traces are shown in Figure 3.2B. Again good quality cRNA is shown 
in blue, there are no distinct peaks detected and the small shoulder on the left of the 
curve is expected. This is because the cRNA represents only the mRNA population 
and should not contain the highly abundant ribosomal RNA molecules which make up 
the majority of a total RNA sample. A poor quality cRNA trace is shown in green in 
Figure 3.2B where the curve is again shifted leftwards meaning the cRNA contains 
many small molecules indicating the synthesis reaction was incomplete. Only 
reactions which when quantified achieved at least 35pg of cRNA were assessed on 
the bioanalyser and subsequently hybridised to Affymetrix GeneChips. All RNA and 
cRNA bioanalyser traces from the samples hybridised to the microarrays are on the 
Data CD inserted in the back cover of this thesis. 
Affymetrix MAS 5.0 software was used to extract data from the microarrays and to 
determine the quality of each hybridisation reaction. Samples which had a Raw Q of 
less than 4 and percentage of genes called present of between 55% and 65% were 
included in the data set. If these parameters were not achieved cRNA was 
resynthesized either from previously extracted RNA, or from newly extracted RNA 
from the second fat pad of the same animal or from fat pads of a new animal. 
Following the quality control checks the complete fat tissue data set 
has 120 chips 
from the RI strains, that is 4 per strain and 5 from each parental strain making a 
total 
of 130 hybridisations. 
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3.2.2 Comparison of data extraction and normalisation methods 
A comparison of two commonly used data extraction and normalisation methods was 
carried out on the data generated in order to determine which method would be used 
to extract and normalise the data for the linkage analysis to identify genes which may 
be involved in SUR pathophysiology. 
Initially these comparisons were carried out on a preliminary dataset which consisted 
of the first 92 hybridised microarrays including 3 from each parental strain in the fat 
tissue. Two normalised data sets were generated using only the 6 parental 
microaiTays: one normallsed using RMA with quantile nonnallsation and the other 
using MAS5.0 followed by median scaling. This allowed a comparison of the two 
data processing methods by determining differential expression between the SHR and 
BN parents. A further data set was derived where all 92 microarrays were normallsed 
using RMA to define some preliminary linkages and eQTL. 
Differential expression was determined in two ways, 1) using a t-test and 2) by 
determining the fold change between the BN and SHR parental strains. A two tailed 
t-test with correction for unequal variance was carried out on the parental RMA and 
median scaled data sets to compare the three SHR microarray outputs to the three BN 
outputs. The results of the t-tests were then compared with each other to determine 
the extent of overlap using two normalisation methods. The numbers of genes 
determined to be significantly differentially expressed were similar, approximately 
I 100 (Table 3.2), however only 506 probe sets were differentially expressed in both 
data sets (P<0.05) indicating that they are truly differentially expressed since they 
were deteced by two different methods. Figure 3.3 is a comparison of t-test 
P-values 
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from both data sets; the yellow shaded areas highlight the probe sets which are 
significant in both data sets with increased significance depicted by darker shading. 
There are many genes in Figure 3.3 and Table 3.2 that are significant in one but not 
both data sets indicating that while the number of genes at each level of statistical 
significance is similar the composition of the gene lists are different. 
A second measure of differential expression, fold change, was determined between 
the parental strains by first determining the mean for BN and SHR from the three 
expression profiles and then using the following formula to calculate the fold change, 
so that the fold change is always SHR relative to BN. 
IF SHR>BN (SHR/BN) or IF SHR<BN (-I /(SHR/BN)) 
Table 3.3 shows the numbers of genes at various ranges of fold change. Most genes 
(14,574) fall in the range of -1.49 to +1.49 fold change and are considered not 
differentially expressed in this analysis. 
Figure 3.4 is a volcano plot of the t-test P-value against fold change for both sets of 
normalised parental data. The blue points represent MAS5.0 median scaled 
data and 
the red RMA normalized data. The median scaled data generates a much wider 
spread of fold change values than the RMA processed data. 
The shaded areas 
represent the probe sets which have arbitrary cut-offs of greater than 
2 fold change 
and p<0.0 I- 
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Table 3.3 Fold Change of fat tissue genes 
Fold change 
. 
No. of genes 
>8 1 
7-7.99 1 
6-6.99 3 
5-5.99 7 
4-4.99_ 9 
3-3.99 25 
2-2.99 78 
1.5- 1.99 262 
-1.49-1.49 14574 
-1.5--1.99 793 
-2--2.99 125 
-3--3.99 27 
-4--4.99 10 
-5--5.99 3 
-6--6.99 1 
-7--7.99 1 
-13--13.99 
-16--16.99 
-39--39.99 
A comparison of fold change between the parental strains, with 5 arrays per strain was 
also carried out when the entire data set of 130 microarrays was available and again 
similar numbers of genes were detected as differentially expressed using both 
normalisation methods but the composition of the gene lists was different. In 
collaboration with Dr Enrico Petretto in the Physiological Genornics and Medicine 
group a comparison of false discovery rate (FDR) and reproducibility both within and 
between strains using both normallsation methods was performed. At every threshold 
of significance the expected number of false positives was estimated by the FDR. In 
this differential expression analysis RMA normallsed data showed a consistently 
lower number of false positives when compared to MAS5.0 normalisation (Figure 
3.5) and was therefore selected as the method of choice for subsequent analysis. 
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Figure 3.5 Example graphs showing the FDR and reproducibility in the 
RI strains following different normalisations: a) The FDR at increasing 
levels of significance in the RMA and MAS5.0 normalised data sets. b) This 
graph shows the reproducibility between animals of the same strain 
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3.2.3 Linkage analysis 
The overall aim of the linkage analysis was to treat the expression profiles generated 
as quantitative traits and to perform genome-wide linkage analysis to determ-ine the 
regions of the genome controlling the expression of all 15,923 genes on the 
microarray. Ultimately QTL Reaper (Wang et a]. 2003) was used to achieve this on a 
genome scale as this program can carry out the linkage analysis for the entire data set 
in an automated fashion. QTL Reaper is an extended version of Map Manager QTX, 
the program which was used to detect linkage in the preliminary data set of 92 
normalised microarrays. Map Manager performs linkage analysis of one quantitative 
trait, in this case an expression profile across all the stral I ins, to the genome. Since only 
one quantitative trait can be tested for linkage at a time genes had to be prjoritised 
before being tested for linkage with Map Manager as it is impractical to manually 
input 15,923 expression profiles individually. 
In the initial analyses, genes were prioritised for linkage analysis across the RI strains 
in Map Manager by first determining if they were differentially expressed between the 
SHR/BN parental strains because genes differentially expressed in the parents are 
likely candidates underlying the heritable phenotypic differences in the RI strains. 
Forty seven genes (Table 3.4) were selected from the preliminary data set discussed 
above and linkage analysis was carried out using the Map Manager QTX program 
(Methods 2.9.1). This program performs two point linkage analysis using marker 
regression between all markers in the genetic map and a quantitative phenotype, in 
this case an expression profile, across all the RI strains within an RI panel. 
Genes 
were selected on the basis that they were differentially expressed in the parental 
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strains either, p<0.00014 (n=10) from the t-test or >4 fold differential expression 
(n=39), two of which were in both data sets. Mean expression values per RI strain 
from the RMA non-nalized data set was the input for the analysis. The Map Manager 
output lists the markers which are significantly linked to each trait. All 47 probe sets 
had a linkage with a p<0.05 and the map locations of the most significantly linked 
marker per probe set are shown in Figure 3.6. During this preliminary analysis 
linkages were defined as either inter- or intra-chromosomal depending on whether the 
most significantly linked marker was on the same or a different chromosome to the 
probe set as a cis1trans definition in terms of chromosomal proximity to probe set 
location had not been finalised. Figure 3.6 shows the locations of the most 
significantly linked marker for the 47 genes studied, 15 (shown in red) were intra- 
chromosomal linkages with the inter-chromosomal linkages shown in blue. Only the 
chromosomal location of the marker is known for those linkages in yellow, that is the 
probe sets genomic location is unknown. As a result these linkages cannot be defined 
as inter or intra chromosomal. All of the most significantly linked (p<0.00001) 
markers where the probe set location is known are Intra-chromosoi-nal. 
As stated above Map Manager QTX can only perform linkage analysis 
between the 
expression profiles from I probe set to the genome-wide markers at a time, making it 
impractical to use to analyse all 15,923 expression profiles. Consequently 
QTL 
Reaper was used to carry out the linkage analysis for all probe sets 
(Methods 2.9.1). 
The 120 rmcroarrays generated for the RI strains were nonnallsed using 
RMA, then 
mean expression values were derived for each strain and 
these 30 values used in the 
QTL Reaper analysis to detect linkages across the genome. 
QTL Reaper uses two 
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point linkage analysis to generate a likelihood ratio statistic (LRS) for each marker on 
the RI strain map and determines genome wide significance by permutation testing. 
This permutation testing corrects for multiple testing across the markers but not for 
testing all 15,923 probe sets. Therefore Dr Enrico Petretto carried out FDR analysis 
to account for multiple testing across 15,923 transcripts and thus to estimate a suitable 
threshold of significance for this experiment. 
Following QTL Reaper analysis, marker redundancy was removed from the data sets 
and cis/trans classification of the eQTL was carried out. Marker redundancy removal 
is necessary as often a probe set will be linked to multiple tightly linked markers, that 
is markers which are in the same genomic location, and this results in an inflated 
number of linkages for each tissue. It was decided to merge linkages where markers 
were within I OcM of each other together into one locus and call this locus the eQTL- 
The algorithm was designed by this student in collaboration with Drs Enrico Petretto 
and Caroline Wallace and Michael Muller wrote a program to automate this process 
for all QTL Reaper linkages. This generated non redundant data sets of 2118 and 
2490 eQTL in fat and kidney respectively, at a genome wide significance of P<0.05. 
These were then characterised as cis or trans eQTL by defining a cIS-acting eQTL as 
one where the linkage peak location for a given probe set is within IONlb (up or 
downstream) of its genomic location (Methods 2.9.2). Table 3.5 shows the numbers 
of linkages detected in both the kidney and fat tissue data sets. At genome wide 
significance (permutated P-value 0.05) there are 2118 and 2490 eQTL in fat and 
kidney tissue respectively of which 311 are shared. Table 3.5 also shows the 
numbers of eQTL linked in cis or trans at increasing levels of significance. 
At higher 
significance levels cis acting eQTL are more prevalent. Figures 
3.7 and 3.8 show 
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Figure 3.7 Location of cis-acting eQTL and previously mapped SHR pQTL 1 
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Chromosomes are shown in blue. The arrowheads on the left of each chromosome 
(yellow, fat; red, kidney; green, shared) represent the location of the probe set for each 
cis-acting eQTL with aP< 10-4. Previously identified pQTL in SHR and the RI 
strains are shown on the right of each chromosome. Grey boxes denote pQTL where 
both flanking markers are mapped. White boxes denote pQTL where incomplete 
flanking marker information was available in which case the flanking marker(s) are 
estimated to be at a distance of I OMbp from the peak of linkage. The numbers on the 
pQTL bars correspond to the pQTL table in Appendix 11. pQTL in this Table which 
do not appear in the above Figure are due to lack of physical mapping information for 
the genetic markers that define the pQTL. Gene names, fold change in parental strains 
and public database references for probe sets are given in Tables 3.7 (fat) and 3.8 
(kidney). 
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Figure 3.8 Location of trans-acting eQTL and previously mapped SHR pQTL 
Ij 6 
9 10 11 12 
U 14 16 
17 18 19 20 
pQTL are as described as in Figure 3.7. The arrowheads on the left of each 
chromosome (colours as in Figure 3.7) represent the location of the marker at the 
peak of linkage for each trans-regulated eQTL with P< 10-2 . This threshold of 
significance was chosen because trans-acting eQTLs are expected to have smaller 
effects than cis-acting eQTL. Gene names, fold change in parental strains and public 
database references for probe sets are reported on the Data CD. 
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genome maps illustrating the locations of all cis and trans eQTL with a genome wide 
significance of 10-4 and 10-2 respectively. Details of the cis-acting eQTL are given in 
Tables 3.7 and 3.8 and this information was used as the basis for candidate gene 
selection in Chapter 4. The physiological QTL presented in Figures 3.7 and 3.8 
were curated by this student and represent all metabolic and cardiovascular QTL in 
SHR and are presented in Appendix 11. This work Is described In Chapter 5. The 
eQTL which were defined as trans-acting are shown in Appendix IV, ývbich is on the 
Data CD. 
I reclassified the 47 initial linkages (as in Figure 3.6) as either cis or trans using the 
definition above and the current release of the genome. The location of both the 
marker and the probe set were determined again and therefore could be designated as 
cislo-ans eQTL linkages. Figure 3.9 and Table 3.6 shows the preliminary 47 linkages 
as in Table 3.4 and Figure 3.6 reclassified according to the above cis1trans definition. 
Following this reanalysis the inter-chromosomal linkages were redefined as being 
linked in Ii-ans and one intra chromosomal linkage is now classed as a trans linkage 
because the most significantly linked marker is more than I OMb up or downstream of 
the probe set. Only two unclassified linkages remain where the probe set location is 
still unknown. Six of the 47 linkages are not shown in Figure 3.9 as the marker 
location is not in the current genome assembly. Finally eight of these cis eQTL from 
this preliminary data set remain in the final data set of cis linkages generated when the 
entire data set was available (Tables 3.7 and 3.8). Those whlcb d1d not sbow 
significance in QTL Reaper analysis were no longer considered significant and 
discarded from further analysis. 
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Table 3.6 Initial MapManager linkages reclassified 
Marker 
Probesets Probe set Chromosome 
I 
Linked marker Chromosome 
Control as in 
table 3.4 cis or trans 
UwW11 - nowulateu 
1 377452__at 8 D8Cebrl6s5 8 intrachromosomal C/S 1370428xat 20 Tnfa 20 intrachromosomal cis 1371033_at 20 Tnfa 20 intrachromosornal cis 1387341a_at 18 Rt2 19 extrachromosornal trans 
1398245_at 16 D1 6Rat6 16 intrachromosomal trans 
1390436at 4 D15Rat107 15 unclassified trans 
1386901at 4 Cd36 4 intrachromosomal cis 
1389986_at 1 D7Utr1 7 extrachromosomal trans 
1369764_at 13 D13Rat88 13 intrachromosomal cis 
1370114_a_at 2 D2Rat94 2 intrachromosomal cis 
1369171at 8 D8Rat202 8 (not mapped) intrachromosomal - 1371960at 5 D5Rat39 5 unclassified cis 
1370831at 4D 11 Rat28 11 extrachromosomal trans 
1376742_at 10 Ppy 10 unclassified cis 
1389974_at 3 D3Mit3 3 intrachromosomal cis 
1390048at 10 D7Utr1 7 extrachromosomal trans 
1384717 at 7 D7Rat1 7 7 unclassified cis 
1387178_a_at 20 D20Cerbp97s7 20 (not mapped) intrachromosomal - 
Up - regulated 
1376908_at 1 D15Rat107 15 extrachromosomal trans 
1371241xat 8 D15Rat1 15 extrachromosomal trans 
1371213_at 20 Tnfa 20 unclassified cis 
1369415at 4 D19Utr1 19 extrachromosomal trans 
1374932at 8 D14Rat52 14 extrachromosomal trans 
1369928at 19 D15Ratl 15 extrachromosomal trans 
1370900 at 10 Cacnals 4 unclassified trans 
1367626_at 1 D5Rat147 5 extrachromosomal trans 
1383564_at 1 D15Rat1O7 15 extrachromosomal trans 
at 1371776 2 D2Rat94 2 unclassified cis 
_ 1369110xat 20 Tnfa 20 intrachromosomal cis 
1368718_at 1D1 Rat296 1 (not mapped) intrachromosomal 
1373053 at hits multiple chromosomes Drd2 8 unclassified 
_ 1376845 at 6 D15Rat1O7 15 extrachromosomal trans 
_ at 1387134 10 D15Rat107 15 extrachromosomal trans 
_ at 1388694 20 D1ORat6 10 extrachromosomal trans 
_ 1374527at 5 D5Rat79 5 unclassified trans 
at 1377334 not mapped Tnfa 20 unclassified 
_ 1369202 at not mapped D1 iCebr87sl 11 (not mapped) intrachromosomal 
_ 1371015 at 11 D15Rat1O7 15 unclassified trans 
1391544-at 7 D8Mit5 8 unclassified trans 
Top Ten p- value 
1386901 at 4 Cd36 
4 intrachromosomal cis 
1 388602--at 7 D14Rat52 14 extrachromosomal trans 
at 1379896 10 D1OUtr2 
10 unclassified cis 
_ at 1368334 10 D16Rat14 
16 extrachromosomal trans 
_ at 1373253 10 Slc4a 
10 intrachromosomal cis 
_ at 1376635 16 D16Mit2 
16 intrachromosomal cis 
_ 1374668at 14 D4Rat-2O2 
4 extrachromosomal trans 
1390562 s at 20 D20Mgh5 
20(not mapped) unclassified 
1384717-at 7 D7Rat1 7 
7 unclassified cis 
1386507-at not mapped D5CebrlOsl2 
5(not mapped) unclassified 
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3.2.4 Target probe set sequencing 
In the preliminary analyses (Table 3.4) and the final QTL Reaper analysis (Table 3.7) 
one of the most differentially expressed and significantly linked probe sets is 
1386901 at which maps to the Cd36 gene. This probe set is in a region of the SHR 
genome which contains a deletion and therefore the probe set contains multiple 
sequence variants. Thus the differential expression detected by this probe set is due to 
sequence variation causing differential hybridisation and rather than true differential 
expression. To determine if this occurs repeatedly and if differential expression could 
often be due to strain differences in the Affymetrix probe set region, a subset of genes 
were selected for sequencing from the preliminary data set of 92 microarrays. These 
probe sets were selected because they were linked in cis (with cis meaning on the 
same chromosome in this case) in both the kidney and fat data sets and had significant 
P-values in the initial analyses. 
The entire probe set region was sequenced from cDNA in both the BN and SHR 
parental strains for 20 probe sets. These probe sets had been found to be differentially 
expressed in a Wilcoxon-Mann-Whitney test carried out by Dr Enrico Petretto. This 
WMW test has not been discussed in this thesis because it was carried out on the 
entire data set prior to QTL Reaper analysis before the QTL Reaper program was 
working and was the first analysis of the entire data set. Thirteen of these were found 
to have no sequence variants in the target region. Seven had sequence differences 
with one (1389156_at) having no differences between SHR and BN only with 
both 
strains to the reference sequence. Therefore six probe sets 
have sequence differences 
between the BN and SHR strains within the target sequence from which the 
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Table 3.9: Shmificance of nrohp , ci-t 
bequence Position Probe t- 
probe set t- variant within Probe test P- 
Probeset testP-value Probe detected (1-25) value PM 1374713_ at 0.691367355 1 Yes 18 ýý 
2 0.5064360 
3 Yes 15 0.7712621 
4 0.8589285 
1 
5 0.3766888 
6 0.4809685 
7 0.2768582 
8 0.2441476 
9 0.5662843 
10 0.5436316 
11 0.8482066 79 =at 0.932556116 1 0.2682925 
r 
2 0.3523577 
3 0.5391923 
4 0.4327482 
5 0.4491701 
6 Yes 4 
7 0.3432729 
8 0.1690251 
9 
10 0.3591597 
11 0.4008780 
1376732 at 0.1910972 
2 0.0249391 
3 0.0078297 
4 Yes 25 0.0023640 
5 0.1324638 
6 
7 0.0597369 
8 0.3397299 
9 
10 0.2615884 
11 0.3428103 
1388909 at 11 0.0006084 
2 0.4499054 
3 0.7102861 
4 0.6782551 
5 0.8491689 
6 0.6498156 
7 0.4009926 
8 0.9832181 
9 Yes 10 
10 0.3319991 
11 0.5008514 
1389575 at 0.61064634 1 0.1766404 _ 2 0.3697129 
3 0.2864417 
4 0.4590462 
5 0.2975048 
6 Yes 12 
7 0.3943435 
8 0.1946102 
9 0.2600508 
10 0.3310310 
11 0.3930660 
0 8387 1398387 at 
77t 0.073906424 1 0.1344671 
_ 2 0.1524257 
3 0.1655052 
4 0.0955107 
5 0.0886343 
6 Yes 3 0.0604937 
7 0.1410897 
8 0.1477562 
9 0.1822567 
10 0.2140814 
11 mmmmmm 
0.1478108 
mmý 
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Affymetrix probes are designed which could account for the differential hybridisation. 
Table 3.9 shows a t- test between the 5 parental strains in fat tissue for the probe set 
and each (PM) probe from the raw *. cel file expression data. This data was extracted 
ftom the raw MAS5.0 files for the entire probe set and using DChip 
(http: //biosun I. harvard. edu/complab/dchipo for each probe pair. A t-test with 
unequal variance was carried out using excel and the significantly (P <0.05) 
differentially expressed probe sets and pairs are highlighted in the table. This data is 
not normalised and therefore it is difficult to compare with the final data sets. Of the 
eight polymorphisms detected 6 lie in differentially expressed probe pairs (determined 
using the t-test) and in three of the probe sets these are the only differentially 
expressed probe pairs (1374713_at, 1388909_at and 1389575_at). In these three 
(from 20) cases this differentially hybridisation may account for the differentially 
expression detected. None of the 6 genes in Table 3.9 are included In the data 
presented as the highly significant cis-acting eQTL genes in Tables 3.7 and 3.8 
3.3 Discussion 
The studies described above combined genome wide linkage analysis and global gene 
expression profiling in fat and kidney tissue both of which are important in the 
pathophysiology of the metabolic syndrome. The BXH/HXB RI strain panel was 
used to map the genetic determinants of gene expression in the 15,923 genes 
represented on the RAE230A Affyinetrix GeneChip. The fat data set was generated 
by this student in collaboration with Dr Caroline Wallace of the 
Physiological 
Genomics and Medicine group while the kidney data set which was used 
for 
comparisons and future work was generated by Norbert 
Hubner's group at the MDC 
in Berlin. 
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Prior to carrying out any RNA extraction, cRNA synthesis or microarray 
hybridisations RNA extraction methods were compared using samples from the age 
matched animals and subsequently it was decided to use the Trizol(& protocol to 
extract RNA. The Agilent Bioanalyser was tested and compared to the more 
commonly used RNA formaldehyde gel to deten-nine if it could be used for assessing 
the quality of both RNA and cRNA because it requires 10 fold less sample for 
analysis of RNA quality. Figure 3.1 shows the results of this comparison and since 
the results from the formaldehyde gel were similar the Bioanalyser was used for 
assessment of all samples in the fat tissue data set. 
Two different normalisation methods were carried out and compared using the fat 
data set and the results highlight the importance of non-nalisation procedure when 
utilising microarray data (Figures 3.3,3.4, Table 3.2,3.3). RMA and median scaling 
normalisation followed by a t-test were applied to a preliminary data set of 6 
microarrays, 3 from each of the parental strains. The numbers of probe sets which 
were determined to be significantly differentially expressed were similar when either 
normalisation method was used (approximately 1,100 with a p<0.05), however only 
506 of these probe sets were in common in both data sets. This result gives 
confidence that, even though a significant false positive rate may be expected, the 
large majority of these shared probe sets will be truly differentially expressed while 
also highlighting the difference between data transformation methods. This analysis 
was repeated on the entire data set when completed and similar results were seen, that 
is while both methods gave rise to similar numbers of differentially expressed genes 
the composition of the gene lists was different. The normalisation comparison also 
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allowed the FDR and reproducibility to be tested (Figure 3.5) and RMA had a 
consistently lower FDR then MAS5.0 at each threshold of significance. Considering 
these factors the RMA normalised data was used in the linkage analysis. The 
importance of considering data extraction and normalisation and the effect it will have 
on subsequent data has been reported by other groups (Bolstad et al. 2003; Irizarry et 
a]. 2003, Irizarry et al. 2005). 
Map Manager QTX was used to define some preliminary linkages by first selecting 
genes which were differentially expressed between the parental strains either by fold 
change or detection by t-test in the preliminaray data set of 6 parental microarrays 
non-nalised with RMA. This filtering was necessary because the Map Manager 
program can only be used to link one expression profile to the genome at a time and 
therefore cannot be used to define linkage for all 15,923 genes on the RAE230A chip 
due to the impracticality. The ton probe sets with the most significant P-value and all 
the genes with 4 fold or greater differential expression (n=39) were selected for 
linkage analysis using Map Manager QTX, with 2 occurring in both lists this gave a 
total of 47 (Table 3.4). All had linkages to at least one marker with P<0.05 and the 
most significant linkages for each probe set were mapped onto the genome. The 
distribution of the most significant linkage for each probe set (Figures 3.6,3.9) is 
widespread across the genome however there were two clusters, one on chromosome 
20 at the Turnour necrosis factor (i (Tnfcc) locus, and another on chromosome 15 at 
marker D15Rat]07. Tnf(x has been shown known to be causally related to the 
hypertensive phenotype in SHR and is associated with the pathogenesis of obesity and 
obesity-associated hypertension in humans (Pausova et al. 2003). The 6 probe sets 
that linked to D15RatIO7 are ESTs and the region of the genome surrounding 
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D15Rat]07 was not well annotated on ensembl at the time but seemed to contain 
mainly novel genes. These two clusters were not studied further when the complete 
data set was available since the primary focus of this students' work is in detecting 
and analysing highly significant cis-acting eQTL; also the chromosome 15 clusters 
did not occur in the final data set (Figure 3.7). 
Interestingly of these 47 genes, all probe sets which have a linkage with a highly 
significant P-value (P<0.00001) and that had been mapped were Intra-chromosomal, 
indicating that the most significant linkages are likely to be to cis-acting eQTL. These 
linkages remained as cis when the cislirans definition was refined so that a cis eQTL 
was defined as the most significantly linked marker within I OMb of the probe set. 
This supports the findings of Schadt and Brem (Brem et a]. 2002; Schadt et a]. 2003) 
who also found cis acting eQTL had higher LOD scores than irans acting modifiers of 
gene expression. Many of these initial linkages were not detected in the final data set 
which reflects the fact that in this preliminary analysis the genes had to be filtered on 
parental strain differential expression before linkage analysis could be carried out and 
at that time only 3 parental microarrays were available which meant that no outlier 
detection could be carried out. Outlier detection was carried out on the final data set 
(Methods 2.9.1.2) as it resulted in reduction in FDR (Hubner et a]. 2005). 
Since Map Manager QTX can only perform one linkage at a time a more automated 
approach was used to carry out the linkages of all 15,923 expression profiles to all 
10 11 markers. In collaboration with Dr Enrico Petretto QTL Reaper analysis was 
carried out to detect linkages for each probe set on the microarray. This program can 
be considered as a modified and extended version of Map Manager QTX which is 
119. 
able to process multiple quantitative traits simultaneously and has an inbuilt 
permutation test to account for multiple comparisons which are being made to 
multiple markers. 
The QTL Reaper analysis was carried out on both the fat and kidney RMA normallsed 
data sets to identify linkages for each transcript across the genome. These linkages 
were then collapsed into loci to define eQTL. This redundancy removal step 
eliminated multiple linkages of probe sets to tightly linked markers and defined 2,118 
linkages in fat and 2,490 in kidney at genome wide significance (P<0.05) of which 
311 were shared between the two tissues (Table 3.5). eQTL shared between tissues 
are likely to reflect common regulatory mechanisms and therefore represent genes 
which may be involved in the metabolic syndrome at the whole body level. These 
non redundant eQTL were then classified as being cis or trans where a gene is 
operationally defined as controlled in cis if the most significantly linked marker maps 
to I OMb up or downstream of the probe set. A gene controlled in trans was defined 
as having the most significantly linked marker on another chromosome or more than 
I OMb from the probe set. Table 3.5 shows the numbers of eQTL linked in cis and 
ti'ans at increasing levels of significance, this demonstrates that more significant 
eQTL are cis-regulated. This again confirms the finding of Schadt and Brem who 
found cis eQTL to have higher LOD scores than trans eQTL and may be expected 
since a first order effect is more likely to be under monogenic control and therefore 
be 
more easily detected. 
The plots in Figures 3.7 and 3.8 show the cl .s (at p< 
10-4 ) and trans (at p< 10-2 ) eQTL 
mapped onto the genome alongside all metabolic and 
CVD SHR pQTL. The different 
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levels of significance were chosen to reflect the fact that cis acting eQTL tend to be 
more significantly linked and act as candidate genes underlying the SHR pQTL and 
illustrates the distribution of eQTL across the genome. This will be discussed further 
in Chapter 4. trans eQTL are generally less significant because they represent the 
oligo or polygenic effects of other genes, meaning that since multiple genes are 
influencing expression of the probe set the linkage will not be the same across all 
strains, while a gene controlled in cis is effectively being controlled as a monogenic 
trait. The trans eQTL genes can be used to build up networks and pathways of gene 
expression however this is outwith the scope of this PhD. 
Finally probe set 1386901at which represents the U36 locus was detected as 
differentially expressed and highly significantly linked in both the preliminary 
analysis and the final QTL Reaper analysis. The Cd36 gene was previously identified 
in the Aitman group (Aitman et al. 1999) as an insulin resistance gene in SHR and the 
underlying mutation is due to a duplication at the U36 locus which, in normal rat 
strains, (e. g. BN) results in a single transcribed gene and two pseudogenes. In the 
SHR strain there is a genomic deletion that creates a chimeric gene at the SHR Cd36 
locus (Glazier et al. 2002) which has only one copy of the gene and this copy has the 
5' end of the functional U36 gene and the 3' end of the second pseudogene which 
results in sequence variation at the 3' end of the gene. The probe set (1386901_at) is 
within the part of the gene which is deleted in the SHR strain and is therefore not 
represented in the SHR genome. Therefore the strongly different hybridisation 
signals are expected to be due to the genomIc deletion at the SHR 
U36 locus and 
thus differential hybridisation signals may not always only be due to differences in 
gene expression. Therefore sequencing of the Affymetrix probe set region was 
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carried out in 20 genes to determine what proportion of the genes showing differential 
expression between the parental strains was due to sequence variants as opposed to 
true differential expression. These genes were identified in a WMW test and 6 had 
sequence variants which altered a probe within the probe set. Three of these had 
polymorphisms which coincide with significant differential expression as detected by 
a t-test and one of these three had a SNP in another probe pair which was not 
differentially expressed. This indicates that polymorphisms within the probe region 
do not account for significant numbers of differentially expressed genes which is in 
accordance with other studies, including that of the group at the MDC which 
generated the kidney data set (Hubner et a]. 2005). 
3.4 Conclusions 
The work in this chapter has tested and validated a number of protocols before using 
these to generate a large and potentially valuable data set in a well characterised 
animal model of complex human disease. It has also shown that this integrated 
genome wide linkage analysis and transcriptional profifing approach is feasible for 
mapping large numbers of eQTL in the rat. 
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Chapter 4: Generation and characterisation of a data set of 
differentially expressed cis-acting eQTL genes 
4.1 Introduction 
The overall aim of the work in this chapter was to select and sequence the putative 
proximal promoter regions of a subset of the most significant cis-acting eQTL genes. 
These genes were selected from the set of cis-acting eQTL genes reported in Chapter 
3 and have a fold change greater than 2 in the parental strains and/or a FDR of less 
than 5%, that is p.,: ý 10-4 in both kidney and fat tissue. These cis-actii-ig eQTL represent 
genes in which the differential expression of the gene is thought to be controlled by 
sequence variation in the gene itself It was decided to sequence up to 2.5Kb of 
genomic sequence immediately upstream of the most 5' exon of these genes to detect 
polymorpbisms; this region represents the putative promoter of the genes. These 
polymorphisms could account for the differential expression detected on the 
microarray and therefore underlie the cis-acting 'eQTL. Ultimately the 
polymorphisms detected can be tested in reporter assays to determine their effect on 
transcnption. 
Control of gene expression by cis elements 
Gene expression can be controlled by the gene itself (cis) or by other regions of tile 
genome (Irans). Cis-regulatory elements which can affect transcription include tile 
proximal promoter, enhancer and repressor elements which can 
be located both up 
and downstream and within the gene itself (e. g. in introns). 
There may also be 
alternative promoters which are available in a tissue or temporally specific manner. 
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Gene expression can also be affected by Polymorphisms In the coding region which 
may lead to amino acid differences in the protein. In addition, transcript levels can be 
regulated by nonsense mediated decay whereby a sequence in the 3'UTR is bound by 
another molecule, such as a micro RNA, and this targets that transcript for 
destruction. Polymorphisms which cause loss or gain of sites for nonsense mediated 
decay would lead to differential expression on the microarray. Since the proximal 
promoter, that is the region immediately upstream of the transcription start site 
commonly contains the transcription factor binding sites (including that for RNA 
polymerase) which control expression of the gene, it was decided to sequence this 
region in the genes selected to detect polymorphisms which may be the cause of the 
differential expression seen on the microarray between the strains. Not all genes have 
a well defined promoter therefore up to 2.5Kb upstream of the most 5' exon was 
sequenced in order to attempt to capture the promoter. 
4.2 Results 
4.2.1 Selection and description of genes to be sequenced 
The cis-acting eQTL identified in Chapter 3 in the kidney and fat tissue data sets 
represent a set of candidate genes for metabolic and cardiovascular disease and some 
of the genes may underlie the previously mapped SHR pQTL (Figure 3.7, Table 5.1). 
Therefore it was decided to select a subset of these eQTL genes for sequencing with 
the aim of detecting polymorphisms which could underlie the gene expression 
differences detected on the microarray. These were initially selected from the cis- 
acting eQTL (full data set on data CD) and were prioritised 
for sequencing using the 
following criterlia, the probe set had a FDR of less than 
5% (or approximately p< 10-4) 
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and/or a fold change in the parental strains of 2 or more. This fold change was 
selected as it more likely to be reproducible using qRT-PCR or northem blot and 
results in a manageable number of genes to be tested. A total of 37 genes which 
matched these criteria were selected from the 129 kidney and 97 fat eQTL ]n the data 
set (Table 4.1). In some cases the eQTL was shared between the tissues but not 
always with the same P-value or fold change. These cases are highlighted in Table 
4.1 and are mainly RTJ genes which are involved in immune function and also the 
Cd36 probe set 1386901_at, which is due to polymorphisms in the probe set due to a 
genomic deletion (Chapter 3). Two probe sets, 1374583_at and 1390185_at map to 
the same gene mRNA clecapping enzyme (Dcps). 
The genes to which these eQTL probe sets mapped were studied using the genome 
databases (Uniform Resource Locators (URLs) Ensembl - http: //www. ensenibl. org/, 
NCBI - http: //www. ncbi. nlm. nih. gov/Genomes/ and UCSC - http: //genome. ucsc. edu/) 
to determine the 5'sequence of the gene and thus identify the putative promoter before 
any sequence analysis was undertaken. The gene structures were compared across the 
databases and also comparatively with the mouse and human orthologues to 
determine the most likely 5' exon. The sequence upstream of the most 5' exon was 
defined as the putative proximal promoter and primers were designed to amplify and 
sequence up to 2.5Kb of this region in fourteen genes. Twenty-two genes were 
discarded from any further analysis due to the difficulty in determining the 5' end of 
the gene or the gene not being well characterised and therefore it could not be 
sequenced. However a further four cis-acting eQTL genes were added to this analysis 
1368291_at, 1374429_at, 1371137_at and 1371725_at because they fulfilled either 
the fold change or significance criteria in one of the tissues and were Interesting 
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candidates or had already been partially investigated in the preliminary analysis 
discussed in Chapter 3. This means there were 19 dIfferentially expressed probe sets 
in the final data set, however, two of these (1374583_at and 1390185_at) mapped to 
the same gene, an mRNA decapping enzyme, and therefore 18 genes were 
investigated. 
The 18 genes selected for sequencing in this chapter are detailed in Table 4.2, this 
shows the probe set, the location of the eQTL, which tissue the linkage was detected 
in, the parental QTL Reaper P-value and the gene description used to identify the 
promoter to be sequenced and the current gene discription. 
4.2.2 Sequencing polymorphisms 
In order to sequence the 2.5Kb of putative promoter, primers were designed to 
amplify the region, typically in four overlapping fragments to try and ensure full 
coverage. Fourteen of the 18 genes have polymorphisms within the putati\, e promoter 
sequence and as Table 4.3 shows most have more than one SNP. The Sequencher 
program was used for sequence analysis and all the sequencing related to a probe set 
is stored together and the variants are numbered in Table 4.3 according to the position 
relative to the A nucleotide of the ATG at the translation start site in most cases. 
Three of the PCR fragments failed and were not replaced with new primers and a 
further 2 generated only partial sequence. The final column of Table 4.3 shows 
which probe sets were sequenced and only 2 contained BN/SHR polymorphisms. 
The Sequencher program allows all sequence generated to be complied into cont, gs 
for comparison and a reference sequence can be set, which was the public sequence in 
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these cases. An example of the Sequencher file fon-nat is presented in Figure 4.1; this 
is a contig view and shows all the fragments sequenced in BN and SHR, the primers 
and the reference sequence for the AkrIc6 gene (probe set 1393902_at). In total 76 
polymorphisms were detected and an example sequence electropherogram generated 
for a part of the promoter of the above gene in both BN and SHR parental strains in 
the forward and reverse directions is shown in Figure 4.2. This T to A transversion 
shown on both strands illustrates the quality of sequence generated and coverage of 
the polymorphisms. 
Figure 4.3 is another screen shot from the Sequencher program and displays two 
SNPs and a repeat difference in the aldehyde oxidase (Ao--vl) gene. As the figure 
shows the SHR fragments have a deletion of 14bp in a repeat region and 2 SNPs close 
together. In addition, the genomic reference sequence for this gene has a run of 
NNNs indicating a gap in the public genome sequence which has now been filled with 
the sequence generated in fragment F4/R4. 
Probe set 1368304_at maps to the Hepatic flavin contain i ng-i-nonooxygenase gene 
(Fnio3) on chromosome 13 and lies within an SHR blood pressure pQTL. When 
sequenced the promoter of this gene was shown to have 16 SNPs, 5 single base 
insertions and 5 single base deletions in addition to a 175bp deletion in the SHR 
relative to the BN strain over the 2.5Kb sequenced. This 175bp deletion can 
be seen 
in the gel image in Figure 4.4 which sbows the PCR fragment in BN and 
SHR. 
The probe sets (target region) from 13 of the cis-acting eQTL genes selected were 
sequenced to determine if the differential expression 
detected could be due to SNPs in 
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Figure 4.4 Genomic PCR of fragment 3 in SHR and BN in Fmo3 gene 
The expected size of the product of this fragment is 580bp and this is seen in the BN 
strain PCR. However the SHR strain has a shorter PCR product indicating a deletion 
in the SHR strain in this region. This deletion is 175bp which was detected during 
sequencing. (Table 4.3) 
138. 
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Zm «Iri -in 
the probe region causing differential hybridisation and three were found to contain 
probe set differences. The other five genes were not sequenced in the target region 
because they were found to contain only one or no polymorphisms in the putative 
promoter. Therefore this part of the promoter was not the cause of the differential 
expression thus these genes were discarded from further consideration at this time. 
Prior to this they were mapped onto the genome and this detected some errors, 
1374583_at, 1371725_at and 1375676_at do not map to the genes Dcps, Pim-1 and 
bn7c respectively as the orginal annotations suggested. 
4.2.3 Trans gene sequencing 
Overall 76 polymorphisms in approximately 40Kb of sequence from the putative 
promoters of cis eQTL were detected. To determine if this number of polymorphisms 
is higher than would be expected by chance the 2.5Kb upstream of 8 genes whicli 
were controlled in t7-ans were selected. These genes are controlled in Iral7s and 
therefore the differential expression is regulated by another gene or element located 
elsewhere in the genome. Thus these genes were expected to have fewer 
polymorphisms in their proximal promoters. Table 4.4 details the genes selected and 
the 14 polymorphisms detected within in approximately 20Kb of sequence. This 
means that the there were 69 SNPs in 40Kb (mean 1.725) in the cis-acting genes 
promoters and 13 in 20Kb (mean 0.65) in the irans. Therefore this analysis 
determined that cis eQTL genes have a higher frequency of SNPs within promoters 
than trans genes. The sequence of the primers for the 8 irans-regulated genes is 
shown in Appendix 111. 
139. 
4.3 Discussion 
The genes selected for sequencing in this chapter were dv-acting eQTL genes because 
these represent a group of genes which control their own expression, that is, 
polymorphisms within these genes result in the eQTL linkage and differential 
expression seen in the RI and parental strains. Since the proximal promoter is the 
primary region of a gene involved in gene expression it was decided to sequence this 
in the 18 genes selected. The proximal promoters of genes are not always well 
defined therefore 2.5Kb upstream of the most 5'exon in the genes which represented 
the eQTL probe sets selected was sequenced. 
Thirty-seven genes from both the fat and kidney data sets were found to be both 2 fold 
differentially expressed between the parental strains and have an QTL Reaper p< 10-4 
Many genes had a significant eQTL linkage in both fat and kidney data sets, however, 
most of these were RT type genes which are involved in antigen presentation in the 
immune system and probably reflect the different immune backgrounds of these 
strains so they were not studied further here. Hubner el al (Hubner et al. 2005) 
demonstrated that RT type genes have many SNPs in the probe region and may 
therefore be causing differential hybridisation. In addition, Cd36, a gene which has 
been shown to be involved in insulin resistance in SHR appears in Table 4.1 but since 
the molecular basis for this differential gene expression is already known it was also 
not studied. The probe sets which mapped to genes that were poorly characterised or 
where there was difficulty in defining the most 5'exon were also not sequenced. 
These probe sets are still good candidates for hypertension and the metabolic 
syndrome however further investigation is needed to identify the most 5' exon and 
therefore the upstream sequence and the promoter. The aim here was to detect 
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polymorphisms in the promoter region which may underlie differential expression 
therefore genes were selected which had a distinct 5' exon. 
A further four cis-acting eQTL genes were sequenced despite the fact that they only 
met either the fold change or significance criteria in at least one tissue, 1368291at 
and 1371725_at had already been partially investigated in the preliminary analysis 
described in Chapter 3, while 1371137_at maps to the Acyl-coenzyme A oxidase 2, 
(Acox2) which is involved in lipid metabolism making it an interesting candidate. 
The final probe set 1374429at was significant in kidney (P ==0.00064) and had 2 fold 
differential expression in fat and was thought to map to the Proto-oncogene 
serine/threonine-protein kinase (Pim-1) gene. 
Sequencing was carried out in the putative proximal promoter of 18 cis-acting eQTL 
genes and 76 polymorphisms of which 69 were SNPs were detected in approximately 
40Kb. To ensure that this is not the number of SNPs which would be detected by 
chance in a promoter region promoters from eight of the genes which are classified as 
trans-regulated, that is their expression is controlled by another region of the genome 
and not the gene itself were sequenced too. These genes are shown in Table 4.4 and 
were found to contain 13 SNPs in the 20Kb sequenced. This higher frequency of 
SNPs in cis-acting genes is expected since gene expression is controlled by the gene 
itself and therefore would be expected to be mutated in a control region such as the 
promoter, while trans-regulated genes are controlled by a factor which maps 
somewhere else in the genome. A recent study by Doss el al. (Doss et al. 2005) 
shows that cis-acting eQTL reside in regions of the genome which are not inherited 
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IBD from the parental strains. This could also explain the increased SNP frequency 
seen in the cis genes sequenced here. 
Figure 4.2 and 4.3 show sequence electropherograms demonstrating examples of a 
few of the sequence variants detected in the Alo-lc6 and Aox] genes. Within the 
2.5Kb sequence upstream of the Aox] gene there is a run of NNNs in the Ensembl 
database and the primers to amplify fragment F4/R4 were designed to span this region 
and fill in the gap. This gap was filled and the sequence generated was used in 
genome alignments using BLAST against the rat genome at Ensembl and found to hit 
all chromosomes excluding 12 indicating it is a repeat sequence of some kind. 
Figure 4.4 depicts PCR amplification of the upstream region of the Fino3 gene. It 
shows a 175bp deletion in this fragment in the SHR strain which was also 
demonstrated on sequencing. There were also 16 SNPs, 5 single base insertions and 5 
single base deletions in this gene between the SHR and BN alleles. 
The target regions that the probe sets are designed from were sequenced in 13 of the 
18 eQTL genes, those genes in which SNPs were detected. This was carried out to 
determine if the differential expression could actually be due to differential 
hybridisation of the BN and SHR transcripts caused by these polymorphisms. 
Only 3 
of the 13 genes had a SNP in the probe set and the differential expression should 
be 
verified in these genes first in case it is in fact differential 
hybridisation. This analysis 
could be started by deten-nining if the differential hybridisation 
detected is due to the 
specific probe of the II on the microarray which contains the 
SNP as in Chapter 3. 
143. 
Prior to sequencing the target regions the mapping of all the probe sets was 
determined because it is known that there are errors in probe set mapping (personal 
communication, NJD), therefore all probe sets were studied in Ensembl and mapped 
independently using BLAST to get the best location possible. There were two probe 
sets in Table 4.1 that originally mapped to the Dcps gene the putative promoter of 
which was sequenced. However it was found that 1374583_at does not map to Dcps 
and therefore was not sequenced as part of the target region sequencing. The Phn-I 
promoter was sequenced and no polymorphisms were found. Rechecking the 
mapping of this Affymetrix probe set (1374429_at) on a more recent genome 
assembly found that it is on the opposite strand to the Ph-n-I gene and there is no 
known annotated gene in the region. The probe set which maps to the Phn-l gene 
(1369862_at) is not differentially expressed and does not have a cis-acting eQTL in 
either tissue. This is further proof that cis-acting eQTL genes have higher frequency 
of SNPs in the promoter regions. The final probe set which was mapped to the 
4wrong' gene was 1375676_at which mapped to Lin7c, in fact this probe set is on the 
other strand from Lin7c and has no gene associated with it. This was one of the 2 
probe sets which had a SNP in the target region. The sequencing of the Lm7e 
putative promoter detected 4 polymorphisms and probe set 1369610at maps to the 
Lin7c gene with an eQTL reaper P-value of 0.0012 in the kidney data set therefore 
narrowly missing the p, ý 10-4 cut-off for significance. Therefore this gene may still 
merit further investigation. 
ing Not routinely sequencing the target region and the inconsistency in probe set mappi 
highlights some of the limitations of the strategy used. In addition, the coding region 
of the gene was not sequenced and no validation of the 
differential expression or the 
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effect the sequence variants detected have on gene expression has been carried out. 
However, the polymorphisms detected are being investigated by others in the 
Physiological Genomics and Medicine Group by generating luciferase reporter assay 
constructs of the BN and SHR alleles which can then be tested for expression. The 
luciferase assay will allow the polymoi-phisms to be investigated to identify which are 
crucial in altering gene expression. 
4.4 Conclusion 
In conclusion the work in this chapter has investigated sequence variants in the 
proximal promoters of cis-acting eQTL genes to identify polymorphisms which may 
cause the altered expression between the BN and SHR parental strains and provide the 
eQTL linkage in the RI strains. The variants detected are being tested by others in the 
Physiological Genomics and Medicine group in luciferase reporter assays to 
determine their effect on gene expression. 
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Chapter -5: In silico studies: 
comparative mapping 
5.1 Introduction 
pQTL determination and 
The overall aim of the work in this chapter was to investigate the applicability of the 
data set of cis-acting eQTL generated in the rat to human disease gene identification. 
Comparative mapping of SHR pQTL to human QTL for hypertension, dyslipidemia, 
insulin resistance, CVD and type 2 diabetes to determine the syntenic overlap was 
undertaken. As discussed in the Introduction 1.2 these phenotypes are involved in 
the highly prevalent metabolic syndrome and cardiovascular diseases which are a 
major health burden in Westernised society and the SHR is a well established animal 
model of these disorders. Rat cis-acting eQTL genes with genome wide significance 
(p<0.05) which had human orthologues within syntenic regions were identified to 
delineate a data set of potential candidate genes for human hypertension, insulin 
resistance, CVD and metabolic syndrome. This was achieved in a stepwise process 
where first human QTL regions were mapped syntenically to the rat genome and then 
cis-acting eQTL genes were identified within these rat regions. Following this, the 
human ortholog of the rat gene was identified and checked to ensure it was situated 
within the human QTL. In addition the rat pQTL (if any) which overlapped the cis- 
acting eQTL was identified. The genes identified during this process represent 
potential candidates for the metabolic syndrome and CVD and some of these 
candidate genes have an already known biological association in 
human and/or rat 
with the phenotypes mapped. 
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In order to carry out this analysis relevant pQTL were collated from the literature in 
both SHR and human populations. These data were then used to determine which of 
the human QTL were syntenic and had cis-acting rat eQTL within them. 
5.1.1 QTL analysis 
QTL analysis (Introduction 1.1.1) has been utillsed to identify regions of the genome 
influencing complex traits such as hypertension and other metabolic phenotypes, in 
both humans and animal models of human disease. This means there are already 
many regions of the genome implicated in susceptibility to these highly prevalent 
human disorders. Over 300 studies have been carried out in human populations for 
traits involved in the metabolic syndrome and CVD; however due to the difficulties 
discussed in Introduction 1.1.1 relatively few genes underlying these QTL have been 
identified. There has been more success in identifying the genes underlying animal 
models of human diseases since they are inbred strains and can be more easily studied 
for example in experimental crosses. 
5.1.2 Comparative mapping 
Comparative mapping is a powerful tool In genomics because If a DNA sequence is 
conserved across species it is more likely to be involved in gene function and or 
control. In the examples discussed here the organisms being compared are also in 
similar disease states therefore the DNA sequences being investigated may 
be more 
likely to be involved in the pathogenesis of that disease. One example of this 
approach, published by Wang et al (Wang et al. 2005) used mouse/human 
comparisons to identify novel candidate genes for atherosclerosis. 
This thesis extends 
the use of comparative mapping by suggesting candidate 
human genes from the rat 
147. 
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eQTL identified in Chapter 3 using the method outlined in Section 5.1. Figure 5.1 
shows an example of one rat chromosome (9) with the human syntenIc regions 
plotted. Alongside are the QTL rnaps in both rat and human with only the 
hypertension QTL selected. This plot was derived using VCmap which is a 
visualisation tool available at the Rat Genome Database (RGD) (http: //rgd. mcýý,. edu/). 
In this chapter the genomic locations of the syntenic blocks and thus the synten1c QTL 
were used to identify rat eQTL that reside within the syntenic regions and which may 
underlie these QTL. 
5.2 Results 
5.2.1 Collation of QTL in SHR and humans 
As previously mentioned SHR is a widely studied rat model of insulin resistance and 
hypertension and therefore many genome wide studies have been conducted 
identifýing SHR pQTL for hypertension, insulin resistance and dyslipidemia. Many 
of these published studies have been reported in RGD therefore I used this as the 
starting point in generating a comprehensive list of all SHR pQTL. The data from 
RGD was checked against the original reference to ensure the reported peak of 
linkage, including markers, and LOD score or P-value were consistent with the 
published paper. At the time this analysis was carried out RGD had 98 QTL in SHR 
strains which were relevant to hypertension, metabolic and CVD phenotypes in the 
database. An extensive literature search was also carried out to identify any further 
SHR pQTL not already in RGD. Also pQTL mapped in the RI strains themselves 
were included, some of which were unpublished (M. Pravenec, unpublished). 
This 
generated a list of 120 pQTL in SHR for CVD and metabolic phenotypes 
(Table 5.1) 
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which was used in the eQTL exp lorer program developed in the Physiological 
Genomics and Medicine group to visualise the eQTL data (Mueller et al. 2006). 
Figure 5.2 is the original database schema for eQTL explorer and demonstrates how 
data generated for this thesis, both in this chapter and in Chapter 3 has been used by 
others in the group. Identification of eQTL within these already known pQTL makes 
that eQTL more interesting as a potential candidate gene underlying the pQTL. An 
example is shown in Figure 5.3 where the probe sets (1367689_a_at and 1386901_at) 
shown map to the Cd36 gene and are controlled in cis in both fat and kidney tissue. 
Mutations within this gene are known to underlie the insulin resistance and altered 
fatty acid metabolism seen in the SHR strain, which is shown by the pQTL (pQTL 
Irgl) on the right side of the chromosome. Therefore other cis-acting eQTL which lie 
within these already mapped pQTL make attractive candidates genes for those 
particular phenotypes. 
This collation was repeated for QTL in human populations by again looking at RGD 
initially and then carrying out an extensive literature search for genome wide scans for 
metabolic syndrome, hypertension, obesity, dyslipidemia, insului resistance and type 
2 diabetes. The results of this are shown in Table 5.2 which reports a list of 286 QTL 
in multiple human populations. This list includes some QTL which do not reach the 
Lander and Kruglyak thresholds of 3.3 and 1.9 for significant and suggestive linkage 
respectively (Lander and Kruglyak 1995). The non significant QTL were Included 
when they overlapped with other QTL and therefore provide supporting evidence that 
this region of the genome is important in the phenotype studied. 
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Table 5.2 Human POTL list 
number SYMBOL CHROMOSOME LOD P-VALUE QT1. 
_classification QTI-11 BP17 H 1 0,0162 Blood Pressure 
QTL2 BP18 H 1 0.0263 Blood Pressure 
QTL3 BP25 H 1 3.5 Blood Pressure 
QTL4 BP45 H 1 1.77 0.00218 Blood Pressure 
QTL5 BP5 H 1 2.96 Blood Pressure 
QTL6 BP9_H 1 3.9 Blood Pressure 
QTI-7 BWI 2_1-1 1 2,32 Body Weight 
QTL8 BW19 
-H 
1 33 Body Weight 
OTL9 BW3 
-H 
I 2. D9 0.00095 Body Weight 
OTLIO BW57_H I 1 0 000 1 Body Weight 
QTL II BW60-1-1 1 2.2 0-0006 Body Weight 
OTL. 112 BW71-H 1 0 0099 Body Weight 
OTLI3 1 2.6 Type 2 Diabetes 
QTI-114 1 19 Type 2 Diabetes 
QTLI5 1 2ý5 0.000078 Lipid Levels 
QTI-116 1 3.81 Lipid Levels 
OTLI7 1 4.295 Type 2 Diabetes 
QTLI8 1 3.7 Lipid Levels 
QT1.119 1 2.33 Type 2 Diabetes 
QTL20 1 4.5 <-00001 Metabolic Syndrome 
OTL21 1 3.71 0,00002 Metabolic Syndrome 
OTL22 1 104 0.00018 Type 2 Diabetes 
OTI 23 BPIO-H 2 392 Blood Pressure 
QTL24 BP23_H 2 3,36 Blood Pressure 
01 L25 BP37_H 2 2.96 Blood Pressure 
OTL26 BP46 H 2 226 0 00062 Blood Pressure 
QTI 27 HW1 3_H 2 342 Body Weight 
QTL28 BVV2-H 2 4.04 Body Weight 
OIL29 BW33 I1 2 15 0 0075 Body Weight 
OTL30 BW53 H 2 1 16 Body Weight 
QTI 31 SlFP2_H 2 495 0 0000009 Hormone level 
QTL32 2 NULL ()C)o8g Blood Pressure 
OIL33 2 NULL 0 Di93 Blood Pressure 
OTL34 2 NULL 00353 Blood Pressure 
QTI 35 2 NUI 1 00007 Blood Pressure 
QTL36 2 2.84 NULL Blood Pressure 
OIL37 2 2 Body Weight 
OTL38 2 26 Lipid Levels 
QTI 39 2 23 Type 2 Diabetes 
QTL40 2 35 Body Weight 
01 L41 2 2.32 0.000009 Lipid Levels 
OTL42 2 39 Type 2 Diabetes 
QTt 43 2 256 Obesity in T2 diabetics 
QTL44 2 33 Obesity in T2 diabetics 
OIL45 2 23 Liptd Levels 
OTL46 2 268 Body Weight 
QTI 47 2 359 Blood Pressure 
QTL48 2 2.22 0 0007 Metabolic Syndrome 
OIL49 2 2.07 0.001 Metabolic Syndrome 
OTL50 2 334 0 0004 Metabolic Syndrome 
QTI 51 2 0 0047 Blood Pressure 
QTL52 2 27 oOO6 Type 2 Diabetes 
OIL53 2 34 Lipid Levels 
OTL54 BP24 H 
- 
3 29 Blood Pressure 
QTL55 BP30 H 
- 
3 2.03 Blood Pressure 
OTL56 BP36 H 
- 
3 4.134 Blood Pressure 
OTL57 BP51 H 
- 
3 1.27 0.00787 Blood Pressure 
QTL58 BFDI H 3 3.94 Body fluid distribution 
OTL59 BWIO H 
- 
3 18 0.002 Body Weight 
QTI-60 BW1 1 H 
- 
3 4-3 0.000004 Body Weight 
OTL61 BW23 H 
- 
3 3.45 Body Weight 
OTL62 BW24 H 
- 
3 2.03 Body Weight 
OTL63 BW88 H 3 3,54 0,009 Body Weight 
OTL64 3 3.91 Type 2 Diabetes 
OTL65 3 2.64 0.0004 Lipid Levels 
QTL66 3 2.6 Body Weight 
QTL67 3 411 Llpid Levels 
OTL68 3 4.67 0.00()0()4 Type 2 Diabetes 
OTL69 3 3.13 0. ()001 Type 2 
Diabetes 
OTL70 3 2.47 0ý0004 Lipid Levels 
QTL, 71 BPI H 4 39 Blood Pressure 
QTL72 - BP26 IA 4 3.2 Blood 
Pressure 
01 L73 - owl ti 4 92 
Body Weight 
OTt 74 - BW1 5H 4 45 0 D00003 
Body Weight 
QTI 75 pW4-H 4 209 0 0()096 
Body Weight 
QTL76 HRTRTI_H 4 3.9 (). 00435 
Heart rate 
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Human QTL 
number 
RGD_Q I 
SYMBOL CHROMOSOME LOD P VALUE QTL classification 
OTL77 4 255 0266 Body Weight QTL 78 4 239 Obesity in T2 diabetics QTL79 4 23 0,004 Type 2 Diabetes 01 L80 4 4.11 Lipid Levels OTL81 4 273 Type 2 Diabetes 
QTI 82 4 2" Blood Pressure 
OTL83 EP21 
-H 
5 0.0785 Blood Pressure 
OTL84 BP47 
-H 
5 2.8 0-00016 Blood Pressure 
OTL85 BFD2 
-H 5 4.49 Body fluid distribution OTL86 BW61 
-H 
5 2A 0.0004 Body Weight 
OTL87 BVV72 
-H 
5 0-0039 Body Weight 
OTL88 SWO-H 5 1.9 0-00 17 Body Weight 
QTL89 5 2.28 0.397 Body Weight 
QTL90 NULL 5N ULL 00076 Blood Pressure 
QTI-91 NULL 5 NULL 0.0309 Blood Pressure 
OTL92 5 2.56 Obesity in T2 diabetics 
QTL93 5 4-1 0.0000077 Hormone level 
QTI. 94 5 2.8 Type 2 Diabetes 
QTL95 5 2.36 0-0004 Type 2 Diabetes 
OTL96 5 2.4 0.00044 Type 2 Diabetes 
QTL97 5 3.64 0.0002 Lipid Levels 
OTL98 5 3.64 0.0000212 Type 2 Diabetes 
QTL99 BP4_H 6 2.5 Blood Pressure 
OTL100 BF D3--fl 6 2.79 Body fluid distribution 
OTLIOI BFD4 H 6 252 Body fluid distribution 
QTI 102 PW14_H 6 1 24 Body Weight 
QTLI03 BW5-H 6 1.77 00021 Body Weight 
01 L104 DW54_H 6 1.53 Body Weight 
OTL105 BW9 H 6 27 0 0002 Body Weight 
QTI 106 NUI 1 6N UII <0 000 1 Blood Pressure 
QTL 107 6 2.49 0 297 Body Weight 
01 L108 6 22 Body Weight 
OTL 109 6 29 Blood Pressure 
QTL 110 6 49 Type 2 Diabetes 
QTI-111 6 4,2 Type 2 Diabetes 
QI Ll 12 6 5ý5 Body Weight 
OTL 113 6 26 99 Lipid Levels 
QTI 114 6 2 96 Type 2 Diabetes 
QTL1 15 6 3.21 Oý042 Blood Pressure 
01 L1 16 6 33 Body Weight 
OTL 117 6 299 00001 Metabolic Syndrome 
QTI 118 6 258 0 0003 Metabolic Syndrome 
QTLI 19 6 2.9 Lipid Levels 
OIL120 6 2.66 0.00023 Type 2 Diabetes 
OTL 121 6 37 L ipid Levels 
OTL 122 6 41 00001 Type 2 Diabetes 
QTL123 6 3.1 Lipid Levels 
OTL124 BP48 H 7 2-26 0-00063 Blood Pressure 
QTL 125 BFD5 H 7 316 Body fluid distribution 
QTL126 BWICH 7 2.26 0.0006 Body Weight 
QTL 127 BW25 H 7 2.66 Body Weight 
OTLI28 BW26 H 7 2.36 Body Weight 
QTL129 BW27 H 7 1.29 Body Weight 
QTL 130 BW35 H 7 3.83 Body Weight 
OTL131 BW68-H 7 0-0011 Body Weight 
OTL 132 7 3.7 Body Weight 
QTL 133 7 4.73 Blood Pressure 
QTL 134 7 2,6 Blood Pressure 
QTL 135 7 12 Type 2 Diabetes 
OTL136 7 1.9 Type 2 Diabetes 
OTL137 7 2.72 Body Weight 
QTL 138 7 4ý9 0.00001 Body Weight 
OTL139 7 2.4 Lipid Levels 
OTL140 7 2.2 Body Weight 
OTL141 7 2.3 Body Weight 
QTL 142 7 2.05 Lipid Levels 
QTL 143 BPII H 8 1.92 Blood Pressure 
01 L144 BP 19-H 8 00284 Blood Pressure 
OTLI45 BP2 H 8 18 Blood Pressure 
QTI 146 RP49 H 8 2,24 0.00066 Blood Pressure 
QTL147 BW20 H - 
8 3.43 Body Weight 
01 L148 BW552 11 8 3.21 Body Weight 
OTLI49 BW59'-H 8 2 0 001 Body Weight 
OTI 1.50 BW69 H 8 0 ()065 Body 
Weight 
OIL151 BW7 H 8 1.95 Oý014 Body 
Might 
01 L152 SLLP1 H 8 3A 0. ooooil 
tiormone level 
- 8 4 87 0 D00001 Lipid Levels OTLI53 
157. 
Human QTL 
number 
RGD_Q I L_ 
SYMBOL CHROMOSOME LOD PYALUE OTL_classification 
OTL 154 8 31 0 0003 Type 2 Diabetes OTI 155 8 309 Type 2 Diabetes OTL156 8 36 Lipid Levels OTLI57 8 33 Lipid Levels OTL158 8 255 0.00036 Type 2 Diabetes OTL 159 BW62 H 9 2.3 Body Weight OTLI60 NULL 9 NULL 0-0171 Blood Pressure OTLI61 9 2-8 Type 2 D&-"es 
QTL 162 9 2 Type 2 Diabetes 
QTL 163 9 0.0002 Type 2 Diabetes 
QTL 164 9 3-4 0.00004 Lipid Levels 
OIL165 BP52 H 10 1.41 0.00547 Blood Pressure 
OTL166 6PG H 10 25 Blood Pressure 
QTI 167 BW16--H 10 146 Body Weight 
QTL 168 BW22 
-H 
10 2.32 Body Weight 
OIL169 IBW63-1 1 10 27 Body Weight 
OTL 170 10 29 0 153 Body Weight 
CITL 171 10 375 Type 2 Diabetes 
GTL 172 10 2.39 Type 2 Diabetes 
01L 173 10 4.85 Body Weight 
arl- 174 10 207 Type 2 Diabetes 
OTI 175 10 311 00001 Type 2 Diabetes 
OTLI76 10 32 Lipid Levels 
OTL 177 BP22_H 11 0.004 Blood Pressure 
QTL178 OP31-H 11 2.07 Blood Pressure 
QTL 179 EW36-H 11 3,35 Body Weight 
OTLI80 BW64_H 11 2-2 Body Weight 
OTLI81 BW70-H 11 0.0079 Body Weight 
CITL182 11 2.6 Lipid Levels 
QTL 183 11 122 0.001213 Lipid Levels 
OTLI84 11 2.11 0.000009 Lipid Levels 
OTL185 11 2ý5 0-0007 Blood Pressure 
OTL186 11 3.6 Lipid Levels 
OTL187 11 3,08 0.00017 Type 2 Diabetes 
OTI-188 11 3.21 Type 2 Diabetes 
QTLI89 11 2,21 Type 2 Diabetes 
CITL 190 11 2.98 000011 Type 2 Diabetes 
QTI 191 BP53_H 12 1 33 0 00673 Blood Pressure 
QTL192 BP7_H 12 3.44 Blood Pressure 
QI L193 BW3714 12 4-08 0-00001 Body Weight 
QTL 19A BVV58 H 12 23 00001 Body Weight 
QTI 195 BV465-H 12 22 Body kNeighl 
QTL196 12 26 Body Weight 
OIL197 12 22 Type 2 Diabetes 
OTI 1q8 12 406 0.000746 I. iptd Levels 
QTI 199 12 281 Type 2 Diabetes 
QTL200 12 2.05 0 0011 Metabolic Syndrome 
01 L201 12 2.56 Type 2 Diabetes 
OTL202 13 298 Type 2 Diabetes 
OTL203 13 3,2 0 00006 Body Weight 
OTL204 13 2.36 0,004 Lipid Levels 
QTL205 13 128 Type 2 Diabetes 
QTL206 13 286 Type 2 Diabetes 
QTL207 13 32 Blood Pressure 
OTL208 BP54 H 14 143 0.00514 Blood Pressure 
01 L209 BV-128 H 
- 
14 2.15 Body Weight 
OTL210 BV066 14 14 24 Body Weight 
QTI 211 14 39 0 000 15 Myocardial infarclion 
QTL212 14 3,2 0 0000062 Hormone level 
01 L213 14 2.74 0.00019 Type 2 Diabetes 
OTL214 BP32 H 15 269 Blood Pressure 
OTL215 BP8 H 15 o. 000()16 Blood Pressure 
QTL216 NULL 15 NULL 0-0033 Blood Pressure 
OTL217 NULL 15 2.94 NULL Blood Pressure 
OTL218 15 2.3 Body Weight 
QTL219 15 3.29 o. o00054 Lipid Levels 
OTL220 15 2 Type 2 Diabetes 
OTL-221 15 3.11 0.000288 Lipid Levels 
OTL222 15 2.19 0. ooI38 Type 2 Diabetes 
OTL223 15 2.28 Type 2 Diabetes 
OTL224 15 3.88 Upid Levels 
OTL225 H BP27 16 32 Blood 
Pressure 
OTL226 _ BP33 H 16 274 Blood 
Pressure 
QTI 227 BW29 H 16 255 
Body Weight 
GIL228 NULL 16 NULL 00314 Blood 
Pressure 
01 L229 16 21 
Body Weight 
OTL230 16 321 
Body Weight 
158. 
m 
Human QTL 
number 
RGD_QTL_ 
SYMBOL CHROMOSOME LOD P_VALLIE OTL_classification 
OTL231 16 433 0 000(M8- Lipid Levels 
QTL 232 16 36 0 00002 1 ipid Levels 
OTL233 BP14 
-H 17 1.9 Oý0029 Blood Pressure QTL234 BP15 
-H 
17 0-025 Blood Pressure 
QTL235 BP16 
-H 17 0 0004 Blood Pressure OTL236 OP20-H 17 0.0256 Blood Pressure 
QTL237 EP34 
-H 
17 2.16 Blood Pressure 
OTI-238 BP35 
-H 
17 Oý0001 Blood Pressure 
OTL239 BVV30_H 17 247 Body Weight 
OTL240 BW31-H 17 1 87 Body Weight 
OTL241 BW55_H 17 1.34 Body Weight 
OTL242 BW56_H 17 2.33 Body Weight 
OTL243 SLEP3_H 17 4,97 0.0003 Hormone level 
QTL244 17 3 0.0119 Body Weight 
OTL-245 17 3 0.003 Type 2 Diabetes 
OTL246 17 2.29 Lipid Levels 
QTL247 17 2.48 Lipid Levels 
OTL248 17 2A Body Weight 
QTL249 17 3-3 0-0001 Type 2 Diabetes 
OTL250 17 12 Type 2 Diabetes 
0 TL251 BP 13 H 18 2.09 Blood Pressure 
OTI 252 PW32_H 18 23 0 00097 Body Weight 
QTL253 BV67_H 18 19 0,001 Body Weight 
01 L254 NULL 18 NULL 0.016 Blood Pressure 
OTL255 NULL 18 46 NULL Blood Pressure 
QTt256 NUt 1 18 26 NULI Blood Pressure 
QTL257 NULL 18 3.21 NULL Blood Pressure 
01 L258 18 3.53 Body Weight 
OTL259 18 46 00000021 Blood Pressure 
QTt 260 18 3,79 Type 2 Diabetes 
QTL261 18 2-6 Blood Pressure 
01 L262 18 2.05 Lipid Levels 
OTL263 BP3_H 19 2.4 Blood Pressure 
OTL264 BP50-H 19 2.1 0.00094 Blood Pressure 
OTL265 BW34-H 19 1.5 0.0063 Body Weight 
QTL266 19 3.59 0-042 Body Weight 
QTL267 19 26 Type 2 Diabetes 
QTL268 19 3,59 Oý000005 Lipid Levels 
OTL269 19 218 0.0004 Type 2 Diabetes 
QTL270 19 3-89 0.00002 Lipid Levels 
OTL271 19 223 0 0007 Lipid Levels 
OTL272 BP29 H 20 Blood Pressure 
QTL273 BWl 7-H 20 15 Body Weight 
01 L274 BVJ6-H 20 1.64 0 003 Body Weight 
OTI. 275 20 306 0 00009 Body Weight 
QTL276 NUI L 20 NUI, 1 0024 Blood Pressure 
QTL277 20 23 Type 2 Diabetes 
OTL278 BP12 
-H 
21 2,82 Blood Pressure 
OTL279 NULL 21 NULL 0.0234 Blood Pressure 
OTL280 21 3,9 Lipid Levels 
QTL281 BP38 
-H 
22 2-07 Blood Pressure 
01 L282 8P55-fi 22 1.54 0.00383 Blood Pressure 
OTL283 22 34 0 0001 Type 2 Diabetes 
QTi 284 22 249 0 0004 Metabolic Syndrome 
OTL285 BP28 
-H 
x 3-3 Blood Pressure 
OTL286 BP39 H x 241 Blood Pressure 
Footnotes 
Shading is to separate chromosomes 
An extended version can be found on data CD containg more description and references 
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5.2.2 Identification of cis-acting human candidate genes 
cis-acting human candidate genes were identified by first determining the region of 
the rat genome which were syntenic to the 286 human QTL In Table 5.2 and 
identifying any cis-acting eQTL within these regions. This analysis was carried out in 
collaboration with Nicholas J Dickens of the Physiological Genomics and Medicine 
group. I defined the strategy and thus algorithm for identifying syntenic regions and 
then mapping eQTL within these regions and looking for human orthologs and 
Nicholas Dickens automated the process. The 286 human QTL identified as 
described above were mapped onto the rat genome and 253 of these have a defined 
syntenic rat region. cis-acting eQTL with a genome wide significant P-value which 
were located within these syntenic regions were then identified. This detected 711 
eQTL which had complete marker and probe set mapping information within 163 of 
the human QTL. A further 93 eQTL were identified; however these were discarded 
due to insufficient mapping infori-nation, such as that the markers or probe set position 
could not be determined. Therefore the syntenic regions and eQTL infori-nation could 
not be derived. The rat gene corresponding to the eQTL was determined using the 
Ensembl annotations of the Affymetrix probe sets. The human orthologs of these 
genes were identified and checked to ensure they were located within the 
corresponding human QTL. This data was collapsed for presentation in the thesis 
(complete table on data CD) and Table 5.3 contains 142 rat eQTL (with the human 
and rat orthologs and their GO classifications) that are contained within 
human QTL 
and are therefore candidate genes for human disease. The rat pQTL are also shown 
in 
this table and 34 of these 142 genes do not map within a rat 
QTL for metabolic 
syndrome traits. The table was collapsed because many of the rat eQTL 
mapped to 
multiple human QTL. Also 23 rat eQTL occur in 
both kidney and fat tissue and are 
160. 
classified as shared in Table 5.3 while 53 and 71 rat eQTL were unique to fat or 
kidney respectively. During this analysis a further 8 probe sets were removed for 
various reasons, which are shown in Table 5.4. Of the 142 eQTL linkages in Table 
5.3 there are 135 unique probe sets and of these 98 and 93 have Ensembl gene 
161. 
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annotations in the rat and human respectively. Thirty-three are known genes in both 
rat and human and 37 have no information attached. For the eQTL genes with some 
information an extensive literature search was carried out to determine possible 
functions and any known involvement in type 2 diabetes, hypertension and other 
metabolic syndrome traits. This search included OMIM, Pubmed, Genecards and 
Google in order to gather as much information as possible. 
5.3 Discussion 
In this chapter comparative mapping of human QTL for metabolic and CVD 
phenotypes to both the rat and mouse was carried out to identify genes which may 
play a causal role in human disease. In the rat, eQTL in the fat and kidney tissue data 
sets were identified from within the regions of the rat genome which were syntenic to 
the human QTL. Table 5.3 details the 142 eQTL, their rat genes and the human 
ortbologs wbicb delineates a set of genes wbicb merit testing in buman populations. 
This analysis also identified a gene (Cd36) which has already been shown to underlie 
an insulin resistance QTL in both humans and rat. 
The first step in the analysis was to gather all the QTL for the relevant traits in both 
rat and human and this data is presented in Tables 5.1 and 5.2 respectively. The next 
stage was to identify syntenic regions of the rat genome to all the human QTL and 
determine which of these rat regions had cis-acting eQTL within them. A complete 
data set of 711 eQTL was identified which was processed to give the 142 eQTL 
presented in Table 5.3. Ninety three of the 711 eQTL were discarded as good 
mapping information was not available either for the probe set and/or the marker. 
Ensembl map locations were used to identify the regions of the genome to which the 
170. 
probe sets and markers mapped as these have been shown to be more accurate than 
the Affymetrix locations (NJ Dickens, personal communication). The remaining 618 
eQTL were studied and collapsed firstly by removing any problem probe sets, then 
since many eQTL (and their corresponding genes) mapped to multiple human QTL 
these were combined to make one entry in column one (Human pQTL) of Table 5.3. 
Also any eQTL which were identified in both fat and kidney tissue were called shared 
and made into one entry in the table. 
The seven probe sets in Table 5.4 were removed from the gene list (Table 5.3) for a 
number of reasons. In 5 of these the probe set and linked marker are located on 
different rat chromosomes and therefore the linkage is controlled in trans. This 
should not have occurred as all the eQTL selected were cis-acting. However closer 
inspection showed that they are classified in eQTL explorer as cis which is probably 
due to errors in the original mapping data and cis1trans definitioii algorithm which 
used an older genome assembly in which the marker and probe set did map to the 
same chromosome. These would have been classified as cis, however on reassembly 
of the genome the marker or probe set are now mapped to a different chromosome and 
since the mapping unclear they have been removed. Probe set 1383734_at linked to 
42 markers on 8 different chromosomes however all were classified as cis-acting 
eQTL. This could be due to the SDP of the markers, or missing genotypes within the 
marker set which would create false linkages. All eQTL to this probe set were 
removed as it is not clear which are real and these markers were not well 
characterised. The final probe set in this table, 1375655_at mapped 
to chromosomes 
9 and 18 with both of these linking to the same marker and 
therefore the chromosome 
18 linkages were removed as these are a trans linkage. 
171. 
The final gene list in Table 5.3 consists of 142 eQTL linkages representing 135 probe 
sets, which means that 7 probe sets occur twice. Three of these have two eQTL 
linkages in the same tissue but to two different markers with a different P-value while 
two probe sets have a different eQTL in fat and kidney tissue. Probe set 1377614_at 
has one linkage in fat and one in kidney which are syntenic to human chromosome 10 
and 16 respectively. Since the orthologous human gene resides on chromosome 16 
the eQTL linkage in kidney which is also syntenic to human chromosome 16 is more 
likely to be the true synteny in this case. Probe set 1389142_at occurs twice as two 
eQTL with linkage to different markers with different P-values which syntenically 
link to human chromosomes 2 and 15. The gene (PLDN) represented by this probe 
set is located on hurnan chromosome 15. The duplication in the table seen in the 
previous two examples occurs because the fat and kidney linkages have different peak 
markers due to the cislti-ans definition and can therefore link to syntenically different 
human chromosomes. Finally, one other gene (FHL2 in human/Slim3 in rat) has 2 
probe sets associated with it (1369313_at and 1371951_at) and both are linked in cis 
to the same marker with a similar P-value. 
The annotations of the genes in Table 5.3 were manually studied, using OMIM, 
Pubmed and Google, to determine if any know relationship with type 2 diabetes, 
hypertension or other metabolic syndrome traits existed. One gene which was 
identified, Cd36, has been shown to underlie insulin resistance and altered long chain 
fatty acid metabolism in both humans and SHR (Introduction). 
This gene was first 
identified as underlying SHR insulin resistance and defective 
fatty acid metabolism 
and these phenotypes were rescued by transgenic expression of 
Cd36 in this strain. 
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When tested in human populations Miyaoka el al found U36 deficient patients have 
increased concentrations of plasma lipids and insulin resistance. It has been suggested 
that U36 deficiency is a "monogenic form" of metabolic syndrome which is in 
accordance with it having a c4s-acting eQTL with very high P-value. There are other 
genes which were detected which have a known role in metabolic syndrome traits. 
One of these, glutathione S-transferase mu-type 1, (Gstm]), is involved in the cellular 
response to oxidative stress. This gene has a strong cis-linkage (p.,: ý10-5) In kidney 
tissue, is approximately 2.4 fold differentially expressed between the parental strains, 
and lies in a cluster of blood pressure QTL on rat chromosome 2. GsIml has been 
implicated previously in hypertension in genetic studies in SHRSP (McBride et a]. 
2003; McBride et a]. 2005) and hurnans (Rice et a]. 2000). In the SHRSP strain, 
Gsti771 shows a reduced expression relative to WKY and BN and thus SHRSP 
(McBride et a]. 2005) has higher levels of superoxide, a reactive oxygen species 
(ROS); these are implicated in diabetes, obesity and hyperlipidaemias. Another gene 
Sex Hormone-Binding Precursor (SHBG) binds testosterone and thus affects the 
amount of free testosterone in the blood. Testosterone modulates blood vessel 
resistance and arterial blood flow and decreased levels of both testosterone and SHBG 
have been associated with increased SBP, DBP and hypeilension in both men 
(Svartberg et al. 2004) and in postmenopausal women (Lapidus et al. 1986; Rexrode 
et al. 2003). Ain association was found between decreased levels of SHBG and 
increased CVD events in both studies. Two common polymorphisms in the 
prothrombin gene, which is also present in Table 5.4 is associated with elevated 
plasma prothrombin and increased risk of venous thrombosis and ischen*u'c stroke 
(Catena et a]. 2005; Wakii-n-Ghorayeb et a]. 2005). One 
final example is that of the 
growth hon-none receptor gene (GHR). A SNP within this gene results 
in a leu 526 -->Ile 
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substitution which influences HDL levels in family members who also had a mutation 
in the LDL receptor which causes familial hypercholesterolemia (Takada et al. 2003). 
The above examples demonstrate the feasibility of this approach in identifying 
potential candidate genes using comparative mapping. Many other tgenes whi have 
no know association exhibit biological characteristics that make them plausible, 
positional candidates for human metabolic and cardiovascular disease and merit 
testing in human populations. For example, like Gstinl, Ao-Y] is also involved in the 
cellular response to oxidative stress and resides In a blood pressure pQTL In both rat 
and human. Gnpat is a key enzyme in the biosynthesis of plasmalogens which are 
important in the protection against ROS and again occurs in a relevant pQTL, blood 
pressure in rat and lipid levels in human. Dgat2 resides in pQTL for body weight and 
blood pressure in both human and rat. DGAT enzymes are involved in triglyceride 
synthesis and catalyse a reaction where diacylglycerol is joined to long chain fatty 
acids (LCFA). Disruption in LCFA synthesis occurs in CD36 deficient patients 
therefore mutations in this gene could have a similar effect. In addition, PMVK Z: ) 
(phosphomevalonate kinase) and BZRP are key enzyme cholesterol biosynthesis and 
flow into the mitochondria respectively, mutations in which could have an effect on 
lipid levels. This means that a group of genes which should be given priority for 
genetic and functional testing in human populations have been Identified and 
increases the likelihood that genes underlie a pQTL in both human and rat. 
Genome databases are dynamic entities and since the above analyses were carried out 
I have looked at RGD again to determine the number of SHR pQTL represented. As 
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of 3 rd May 2006 there are approximately 1100 rat QTL of which 236 are in SHR 
strain combinations with 174 occurring in cardiovascular and metabolic traits. 
Therefore this analysis could be repeated with new QTL added to identify more 
candidates for pQTL that merit genetic and functional testing. 
The data from the human QTL was also used in a comparative mapping study in a 
mouse model of type 2 diabetes, the Irs2 knockout mouse. This mouse model lacks 
the insulin receptor substrate 2 (Irs2) which is a major intracellular target of the 
activated insulin receptor. These mice have peripheral insulin resistance and develop 
diabetes in a few weeks as Irs2 signalling is also required for beta cell adaption to 
insulin resistance (Withers et al. 1998). Gene expression and metabonomic data was 
derived in three tissues, liver, white adipose tissue and skeletal muscle, from Irs2 
knockout mice as part of the BAIR consortium. The genes identified as differentially 
expressed when the metabonomic and microarray data was integrated Nvere 
investigated to determine if they lay within QTL for human and i-nouse inetabolIc 
syndrome phenotypes. The human QTL displayed in Table 5.2 was filtered for 
Lander and Kruglyak significance and only for human QTL whIch were related to 
insulin resistance. This identified 84 genes from the mouse data set which 
had human 
orthologues and are potential candidates underlying human insulin resistance and type 
2 diabetes (KM, JM, TJA unpublished data). 
5.4 Conclusion 
In conclusion the work in this chapter provides valuable insight 
into the uses of 
comparative mapping between rat and human 
for the selection of potential candidate 
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genes for rat and human physiological and pathophysiological phenotypes. Since this 
method detected genes with a known role in insulin resistance and hypertension, key 
features of the metabolic syndrome, this provides validation of this technique for 
generation of a list of potential candidates for human disease using rat eQTL data. 
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Chapter 6: General Discussion 
The overall aim of this study was to use transcriptional profiling in a segregating 
population to Integrate the substantial body of genetic and phenotypic data available 
for the BXH/HXB RI strains by generating and mapping gene expression profiles 
across the strains (and SHR and BN parentals) using DNA microarray technology. 
Following generation of gene expression data, linkage analysis was used to identify 
the genetic determinants of gene expression and then c/S-acting eQTL selected as 
potential candidate genes for human cardiovascular and metabolic phenotypes. The 
specific aims were set as: generate microarray data for a subset of the BXH/HXB 
recombinant inbred strains and SHR and BN parental strains, use linkage analysis of 
the entire microarray data set to identify differentially expressed genes that are 
controlled in cis and in trans, to prioritise genes as candidates for sequencing in the 
promoter region to identify variants which may underlie the differential expression 
and thus biological phenotype in cis-regulated eQTL and finally to carry out 
comparative mapping of cis-acting eQTL to identify candidate genes which 
potentially underlie human disease. 
In Chapter 3 the generation, validation and normallsation of the microarray data sets 
is presented and the linkage analysis and cis1trans determination was carried out. 
In Chapter 4a subset of the robustly mapped (FDR < 5%, approximately p< 
10-4) CjS_ 
acting eQTL genes were examined to identify sequence polymorphisms in 
the 
putative promoters that may explain the differential expression. 
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In Chapter 5a comparative mapping study was carried out to investigate the 
applicability of the data set to human disease gene identification. Human 
physiological QTL for metabolic syndrome traits were mapped to the rat genome and 
cis-acting eQTL in these syntenic regions identified. The human orthologs were 
identified and thus merit testing in human populations as potential candidates 
underlying the pQTL. 
The results presented in Chapter 3 for the microarray and linkage analysis identified 
2,118 and 2,490 non redundant eQTL linkages in fat and kidney tissue respectively at 
genorne wide significance (P<0.05). In addition, eQTL were classified as cIS and 
17, ans-acting and, as demonstrated in previous studies, (Brem et al. 2002; Schadt et al. 
2003, Morely et al. 2004) cis-acting eQTL are more significant. Initial investigations 
carried out on 42 differentially expressed genes between the SHR and BN parental 
strains demonstrated that gene expression is heritable and can be mapped in 
accordance with previous studies (Brem et a]. 2002; Schadt et a]. 2003). These data 
provided the basis to carry out the whole genome linkage analysis using QTL Reaper 
(Wang et al. 2003). Sequence variation in the probe region was investigated in these 
initial genes and it was discovered that 7 had polymorphisms in the target region with 
6 having (a) polymorphism(s) in an actual probe sequence. In three cases these SNPs 
could account for the differential expression because the single probe which contained 
the SNP was determined to be significantly differentially expressed when analysed 
from unnon-nalised data. The analysis in Chapter 3 provided a basis for the work in 
Chapters 4 and 5. 
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In Chapter 4 the sequencing strategy was to identify promoter sequence variants in a 
number of cis-acting eQTL genes as these may account for the differential expression 
detected. The putative promoter was identified by finding the most 5' exon of the 
gene to which the Affymetrix probe set mapped and sequencing up to 2.5 Kb 
upstream of this. A selection of trans regulated genes were also sequenced in the 
putative promoter region to determine if the cis-acting genes had an higher overall 
SNP frequency and it was concluded that they did. The sequence variants detected 
remain to be tested in reporter assays to assess their effect on gene expression. 
In Chapter 5 the comparative mapping detected 142 cis-acting eQTL which represent 
candidate genes underlying both SHR and human metabolic syndrome traits. Some of 
the genes identified in this analysis have a known association with metabolic 
syndrome phenotypes such as hypertension and obesity and thus the other genes 
presented are good potential candidates and merit testing in human populations. 
Overall the results show the potential utility of integrated linkage analysis and gene 
expression, the "genetical genomics" approach, to the study of SHR and human 
metabolic and cardiovascular disease. However there are some points for discussion 
and questions which are raised by the work presented here. 
Major challenges for geneticists in the post-genome era are to map the genetic 
polymorpbisms responsible for variation in disease susceptibility and 
to determine 
their allele frequencies, mode of inheritance and effects in 
different environments. 
While it is relatively easy to localise QTL using genome scans, 
identifying the genetic 
locus, or gene(s), that underlies each QTL requires 
high-resolution recombination or 
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linkage disequilibrium mapping to identify candidate genes, followed by genetic 
and/or functional complementation and gene expression analyses (Mackay 2001). In 
the search for genes underlying complex traits, an approach utilising a combined 
genetic linkage and microarray strategy proved successful in identifying the gene 
underlying the chromosome 4 insulin resistance QTL in SHR (Aitman et al. 1999). 
This approach has also been used to identify other disease genes such as a 
susceptibility gene in a model of experimental allergic asthma (Karp et al. 2000). The 
success of this integrated approach in previous studies of complex traits led to the use 
of this strategy in the studies presented here to identify candidate genes for 
cardiovascular and metabolic phenotypes in SHR on a genome wide scale. The 
approach used in this study combined microarray expression profiling and genoine 
wide linkage analysis following the suggestion of a 'gentical genomic' approach by 
Jansen and Nap (Jansen and Nap 2001) and the first example using yeast (Brem et al. 
2002). 
The gentical genomic approach was utilised in this study in fat and kidney tissue, two 
tissues which are important in the pathophysiology of the metabolic syndrome. Tile 
success of this strategy in identifying genes underlying complex traits is dependant on 
the robustness of the genetic map and the linkage analysis, the quality of the gene 
expression data and the ability to prioritise and identify candidate genes. While no one 
specific gene has yet been definitively identified as the causative gene in any specific 
phenotype many potential positional candidates underlying previously mapped SHR 
pQTL were investigated, and some human candidate genes have also been suggested 
by these analyses. At least two genes with a known involvement in insulin resistance 
and hypertension in SHR, Cd36 and Gstm] respectively have been identified 
by this 
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analysis. This demonstrates the utility of this approach and that some of the genes 
identified will be involved in the metabolic syndrome and have molecular variants 
which underlie the SHR pQTL. 
The advantage of gene expression studies is that the entire (known) transcriptome can 
be assayed in one reaction. However microarray experiments are expensive and the 
large data sets require much data handling and statistics, therefore the experimental 
design, for example tissue type, age of animals and numbers of replicates must be 
carefully considered and optimised. There are many tissues involved iii the metabolic 
syndrome and fat tissue plays an important role since it is metabolically active and 
obesity is a major cause of heart disease and diabetes while the kidney Is critical "I 
blood pressure homeostasis. The tissues used in this experiment were extracted from 
same parental and RI strain animals and several other tissues relevant to the 
pathogenesis of metabolic syndrome were extracted at the same time, and microarray 
data sets are now available for left ventricle and adrenal tissue. The animals were all 
the same age at the time of tissue harvesting and this means the SHR will be both 
hypertensive and insulin resistant. The number of replicates was also considered in 
this study and 4 was chosen as this is lowest number which allows outlier detection to 
be carried out. 
Microarray normalisation methods attempt to remove experimental noise which 
allows easier analysis of the data. Several methods of normalisation exist and many 
comparisons have been carried out and the differences 
between methods well 
documented (Quackenbush 2002; Bolstad et al. 2003; Irizarry et al. 2005). In this 
thesis RMA and MAS5.0 were compared and RMA selected as 
it has been shown to 
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outperform MAS5.0 (Irizarry et al. 2003) and resulted in a consistently lower FDR in 
this data set. 
The previous studies which used genetical genomics (Brem et al. 2002; Schadt et al. 
2003) found that differential expression was highly heritable and that approximately 
one third of genes had at least one eQTL. cis-acting eQTL are non-nally found to be 
more significant which reflects the fact that these represent a first order effect unlike 
trans eQTL which are second order effects and therefore smaller. The work presented 
in this thesis detected similar results. 
In Chapter 4a comparison of SNP frequency between the cis and Irans-regulated 
eQTL genes was undertaken and the higher SNP frequency seen in cis-acting eQTL 
genes may reflect the fact that these genes have a causative variant in their sequence 
or regulatory regions. However it may also be due to the fact that cis-acting eQTL 
genes lie in SNP enriched regions as they tend to be in the regions of the genome not 
inherited IBS between the parental strains. Doss et al (Doss et al. 2005) cletermiiied 
that more than 96% of cis eQTL in their data set lay within regions not inherited IBD 
and this could be tested in the BN/SHR strain combination as and when haplotype 
maps become available for the rat genome. Studying the regions IBD may also be 
helpful when prioritising candidates as non IBD regions (betwent he parents) are more 
likely to be involved in disease. The cis/trans definition is based purely on the 
relative position of the eQTL and the probe set and therefore it is possible that some 
of the cis-acting eQTL may actually be under trans control. 
A test was carried out to 
define the size of the cis eQTL window and I OMb was deten-nined as optimum. 
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One of the weaknesses of this study is that no differential expression validation has 
been carried out to determine if the fold change can be replicated. Some validation of 
differential gene expression in the kidney was carried out by our collaborators at the 
MDC in Berlin (Hubner et a]. 2005) and using qRT-PCR they conformed differential 
expression in 14 of the 15 genes tested. The final gene was an immune gene in the 
RT I locus, which are known to be highly polymorphic and therefore the differential 
expression could be due to these polymorphisms causing differential hybrId'satlon of 
the probe. 
Probe set sequencing was carried out following the promoter sequencing in Chapter 
4. SNPs were detected in 3 of the genes. These SNPs may account for the differential 
expression seen on the microarray and it may be beneficial to verify the expression 
before further analysis. However as it has been previously demonstrated that SNPs in 
the probe region account for very small amounts of differential expression (Hubner et 
al. 2005) it was not decided to routinely sequence the target regions. 
While the aim of the sequencing strategy employed here was to detect promoter 
variants polymorphisms in other parts of the gene could be equally important. 
Variation detected in the 3'UTR could have an effect on post transcription 
modification and nonsense mediated decay wbile coding SNPs could lead to cbanges 
in amino acids and intronic SNPS at intron/exon boundaries may lead to alternative 
splicing. Any or all of these could lead to altered transcription however the promoter 
was focused on in Chapter 4 of this thesis as this is the most likely region 
for 
transcription factor binding sites and alterations In these regions would lead to 
differential expression. 
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Two recent publications presented s trategies which may have been useful when 
selecting genes to sequence. Yaguchi el al (Yaguchi et al. 2005) combined eQTL 
with SNP analysis in the coding region (cSNPs) to accentuate discovery of candidate 
genes in a mouse model of type 2 diabetes. This could be used to identify likely SNPs 
in region under st-udy; however this approach may not be as useful in rat studies as 
there is much less SNP information available. Xie et al (Xie et al. 2005) used a 
systematic comparative genomic method to identify regulatory elements in both the 
promoter and the 3'UTR. They compared human, mouse, rat and dog genornes and 
detected 174 promoter motifs, including some known transcription factor binding 
sites and 106 YUTR motifs. This type of analysis inight be useful when deciding 
which genes to select for sequencing and which nucleotides may be important in 
regulation. 
6.1 Concluding remarks 
Complex traits, such as hypertension and metabolic syndrome are a substantial burden 
on public health. The ability to identify genes which underlie these traits will lead to 
improved prevention and treatment of these disorders and their associated 
cardiovascular risk. 
The results described in this thesis demonstrate the use of a genome wide combined 
y candidate genetic linkage analysis and gene expression using microarrays to identif 
genes which may underlie complex genetic traits in a rat 
disease model. 
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RI 4 
RI 5 
RI 5C 
RI 6C 
Rl 7 
Animal 
Number 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
3 
4 
1 
2 
Investigator RI Strain 
Number 
cw RI 11C 
cw 
FM 
FM 
FM Rl 12C 
cw 
cw 
FM 
FM RI 13C 
FM 
cw 
cw 
FM RI 15 
FM 
cw 
cw 
FM RI 17 
FM 
cw 
cw 
FM RI 18 
FM 
cw 
cw 
FM Rl 20 
FM 
cw 
cw 
FM RI 21 
FM 
cw 
cw 
FM RI 22 
FM 
cw 
cw 
FM RI 23 
FM 
cw 
cw 
FM Rl 24 
FM 
cw 
cw 
FM RI 25 
FM 
cw 
cw 
Animal Investigator Number 
1 cw 
2 cw 
3 FM 
4 FM 
1 cw 
2 cw 
3 FM 
4 FM 
1 cw 
2 cw 
3 FM 
4 FM 
1 cw 
2 cw 
3 FM 
4 FM 
1 cw 
2 cw 
3 FM 
4 FM 
1 cw 
2 cw 
3 FM 
4 FM 
1 cw 
2 cw 
3 FM 
4 FM 
1 cw 
2 cw 
3 FM 
4 FM 
1 cw 
2 cw 
3 FM 
4 FM 
1 cw 
2 cw 
3 FM 
4 FM 
1 cw 
2 cw 
3 FM 
4 FM 
1 cw 
2 cw 
3 FM 
4 FM 
200. 
3 FM RI 26 1 cw 
4 FM 2 cw 
RI 8C 1 cw 3 FM 
2 cw 4 FM 
3 FM Rl 27 1 cw 
4 FM 2 cw 
RI 9C 1 cw 3 FM 
2 cw 4 FM 
3 FM RI 29 1 cw 
4 FM 2 cw 
Rl 10 1 cw 3 FM 
2 cw 4 FM 
3 FM RI 31 1 cw 
4 FM 2 cw 
RI 10C 1 cw 3 FM 
2 cw 4 FM 
3 FM 
4 FM 
Footnotes 
CW indicates Dr Caroline Wallace prepared this sample 
FM indicates this student Fiona Maciver prepared the sample 
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Appendix III Trans gene primers 
Name on tube Probeset Primer name Primer sequence FMI 1369784_at 1369784F1 ACTCTGATTTGGCCTCCAGA 
FM2 1369784R1 AGAAGATGTGCATCGCTCAA 
FM3 1369784F2 TTCGAGGAGAAGGACTCTGG 
FM4 1369784R2 ATGCCAAGGCAGATTGACA 
FM5 1369784F3 TCACCTCACCTCCCTTCATC 
FM6 1369784R3 CTTGCAGACAAGAACCTACCA 
FM7 1369784F4 AATGTTTGGCTGTGGGTCTC 
FM8 1369784R4 TGCCCACTCAAGCTTAGACA 
FM9 1369784F5 TGAGTGGCACCTTTGTTCTG 
FM10 1369784R5 TTCAGGTGAAACAGAAGATCCA 
FMll 1372923at 1372923F1 CCGAAAGGCAGATCAGAGTC 
FM12 1372923R1 TCTGGTGCCTAGCCCAAT 
FM13 1372923F2 CTGGGTCTGTGCCTCATTTT 
FM14 1372923R2 TCTTTGCATCCTTCCCATTC 
FM15 1372923F3 CTCATAGGTTCCTGGGTTGT 
FM16 1372923R3 CAGGAGGTACCTGGGAGTT 
FM17 1372923F4 ATAGCAGCCTCCCTCCCTTA 
FM18 1372923R4 CTCCTCCCGAATAGAGGAT 
FM19 1372923F5 ACCAATGCTGACCTGAAAGG 
FM20 1372923R5 GCTTGGCTCTGAGCACTAAAG 
FM21 1373773at 1373773F1 catgttgacaataagttggtg 
FM22 1373773R1 GAACTCACAGGGAACCCAAA 
FM23 1373773F2 gagatgggctgaaacagagg 
FM24 1373773R2 ttagcaatcgtgctcaacct 
FM25 1373773F3 GACACAGCTTTGACAGACAG 
FM26 1373773R3 ACAGTGGGAAAGCCCAGATT 
FM27 1373773F4 TGAATCTGACTGGGTGAGCA 
FM28 1373773R4 CACAGTACCTTTTTGTGTCTGTCC 
FM29 1385823sat 1385823F1 ACAAACAGTACCCCACTTCCT 
FM30 1385823R1 TTCCTGGGCTGCTAATATGG 
FM31 1385823F2 GATCCGAGAATCTCTCCACT 
FM32 1385823R2 TGCACAGTGCCCATAATACC 
FM33 1385823F3 CGAGGCCCTTAAATCTCCAT 
FM34 1385823R3 acggggatcctccataatg 
FM35 1385823F4 GAATCTATGCCTGCGTAAAGG 
FM36 1385823R4 AGAAGCGAGGAGGGAAGGT 
FM37 1385823f4a tccagggcggagtttcct 
FM38 1385823r4a ctgggctgcgaacaataag 
FM39 1390346_at 1390346FI gtgcctgtagaagcctaa 
FM40 1390346R1 gaaagaccagcacagcc 
FM41 1390346F2 cagttctcagtggactgaat 
FM42 1390346R2 cagtctaggctactacagtg 
FM43 1390346F3 acacttgaagtggcccca9tc 
FM44 1390346R3 atttcgggcacagatgaagat 
FM45 1390346F4 gtctgtttgattggacagtc9t 
FM46 1390346R4 tcgttgttttgcattttcca 
FM47 1390346f4a aaaccccatgctcaatgaa9 
FM169 1369273_a_at NPR3Fl cgagaaagtgaacagcagca 
FM170 NPR3Rl cacccgttgcagagacaag 
FM171 NPR3F2 ggatccatagccggtgttta 
FM172 NPR3R2 acr-aggtctgcaaatgaacc 
FM173 NPR3F3 tgttgcttcggatgttgggt 
FM174 NPR3R3 ggcagctggtgaagaatctc 
FM175 NPR3F4 atttggctgggcgtcagt 
FM176 NPR3R4 cccagactcttccagtga9c 
FM177 NPR3F5 catgaaggactggggtttcct 
FM178 NPR3R5 tgacatccttcagcacagcc 
FM179 NPR3F6 ggtcggtaagcaaagggatt 
FM180 NPR3R6 ctcttctggaaagcctgaaa 
MH33 1369171at MH33gMSTF1 gttcctcagttcacaggaaga 
MH34 MH34gMSTF1 gaactccctcctgaaggcaa 
MH35 MH35gMSTF1 gactaagtctgggtggccaa 
MH36 MH36gMSTFI ctactgacacftctatgccaaa 
MH37 MH37gMSTFI gagatgtcacactaagcccaa 
MH38 MH38gMSTF1 ctggcctgacaggtcctat 
rnhl8l 1370806_at rmt7gFl 
gcctatcagctaacctggca 
rmt7grl ccagggccttgtgcttgcta mh182 
rmt7gf2 gagtaggggatccaaggttt rnhl83 
rmt7gf3 ccctcttaccggaacgct mhl84 
rmt7gr3 ggcttgtgtggccccatggt mhl85 
rmt7gf4 catgccctggatgagcagaa mhl86 
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